pid,text,source,timestamp,url,hcp,therapy,alternative_therapy,insight,comparison_aspect,discussion,sentiment
b047f473-36e7-45ee-b179-338d41491b9f,"ğ‚ğ¥ğ¢ğœğ¤ ğ¡ğğ«ğ ğ“ğ¨ https://lnkd.in/g9XvDJir ğ ğğ­ ğ°ğğ¥ğ¥-ğ«ğğ¬ğğšğ«ğœğ¡ ğ«ğğ©ğ¨ğ«ğ­ ........................................................................................................................................................#Innovation, #Management, #DigitalMarketing, #Entrepreneurship, #Startups, #Leadership, #BusinessGrowth, #SustainableDevelopment, #EconomicPolicy, #HumanResources, #Marketing, #Technology, #Careers, #SocialMedia, #Entrepreneurâ€‹ #olanzapinetabletsmarket #olanzapine #tablets #olanzapinetabletsmarketsize #olanzapinetabletsmarketshare #olanzapinetabletsmarketforecast #finance, #investing, #stockmarket, #crypto, #financialfreedom, #personalfinance, #wealth, #trading, #money, #financialliteracy, #economy #lilly #dr.reddy'slaboratories #apotex #torrentpharmaceuticalsltd. #tevapharmaceutical #https://lnkd.in/eak_Nvd3. #qilupharmaceuticalco.ltd. #https://lnkd.in/eAiZg8hZ. #https://lnkd.in/d7g-zJpX. #https://lnkd.in/d__SR3Q4. #https://lnkd.in/g4CrQXiB. #pkuhealthcarecorp.ltd. #https://lnkd.in/e47XcCFs. #sunshinelakepharmaco.ltd. #https://lnkd.in/euh7zc2r. #https://lnkd.in/eASwENfg. #https://lnkd.in/enB8AEtx.",linkedin,2024-07-05T09:30:07.936Z,https://www.linkedin.com/pulse/global-olanzapine-tablets-market-challenges-82zhc,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
32d7a40b-7b5c-4902-8833-9860636d93b1,#innovation #management #digitalmarketing #technology #creativity #futurism #startups #marketing #entrepreneurship #money #sustainability #inspiration #MarketResearch #BusinessIntelligence #IndustryAnalysis #DataAnalysis #MarketAnalysis #ConsumerInsights #MarketTrends #BusinessStrategy #MarketIntelligence #DataDrivenDecisions #CompetitiveAnalysis #CustomerResearch #MarketingResearch #DataScience #BusinessAnalytics #StrategicInsights #TrendAnalysis #MarketForecast #CustomerBehavior #InsightsDriven **,linkedin,2024-08-23T17:30:05.856Z,https://www.linkedin.com/pulse/south-korea-aripiprazole-tablets-market-applications-ji3nc,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
ed634429-90c3-4bfa-9825-e3bfb6684f58,"ğŸš€ TOP 10 #Biopharma Deals of the Year! ğŸš€

https://lnkd.in/eBKXc5Fk

The past couple of years have seen Big Pharmas whip out their wallets to place high-stakes bets in the red-hot races for antibody-drug conjugates, radiopharmaceuticals, and obesity drugs. Here are the 10 most intriguing deals that caught our attention:

ğŸ’Š Bristol Myers Squibb and Karuna Therapeutics
BMS acquired Karuna Therapeutics for $14 billion, betting on the schizophrenia drug KarXT which could bring in $2.8 billion in sales by 2028.

ğŸ’‰ Roche and Carmot Therapeutics
Rocheâ€™s $2.7 billion acquisition of Carmot secures a pipeline of GLP-1/GIP receptor agonists, with CT-388 showing promising weight loss results in phase 1 trials.

ğŸ‡¨ğŸ‡¦ Novo Nordisk and Inversago Pharma
Novo Nordisk acquired Inversago Pharma for up to $1.07 billion, focusing on CB1 receptor blockers for obesity, with monlunabant now in phase 2 trials.

ğŸ—£ï¸ GSK and Bellus Health
GSKâ€™s $2 billion buyout of Bellus Health aims to lead the chronic cough market with camlipixant, competing against Merckâ€™s gefapixant.

ğŸ§  Biogen and Reata Pharmaceuticals
Biogenâ€™s $7.3 billion acquisition includes Skyclarys, the first approved treatment for Friedreichâ€™s ataxia, with $1.5 billion sales potential by 2030.

ğŸ‹ï¸ Eli Lilly and Versanis Bio
Eli Lillyâ€™s $1.92 billion deal brings in bimagrumab, tested for weight loss without muscle loss, to enhance their obesity treatment portfolio.

ğŸ”¬ Novartis and Chinook Therapeutics
Novartisâ€™ $3.2 billion buyout of Chinook looks promising with atrasentan showing significant improvement in proteinuria in phase 3 trials.

ğŸ’¡ Roche and Telavant
Rocheâ€™s $7.1 billion acquisition of Telavant aims to reset the standard of care in inflammatory bowel disease with RVT-3101.

ğŸŒŸ Bristol Myers Squibb and RayzeBio
BMSâ€™s $4.1 billion purchase of RayzeBio targets the radiopharma space with RYZ101 in phase 3 trials for SSTR-positive tumors.

ğŸ§ª AstraZeneca and Fusion Pharmaceuticals
AstraZenecaâ€™s $2 billion deal with Fusion secures FPI-2265, an actinium-based PSMA-targeted radiotherapy, advancing their radiopharma manufacturing capabilities.

#biotechnology #mergersandacquisitions #pharmaceuticals",linkedin,2024-06-28T18:15:55.805Z,https://www.linkedin.com/feed/update/urn:li:activity:7212519101007622144?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7212519101007622144%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Bristol Myers Squibb', 'specialty': 'Pharmaceuticals', 'affiliation': 'Bristol Myers Squibb', 'geographical_region': 'Global'}","[{'name': 'KarXT', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Karuna Therapeutics', 'approval_status': 'In development'}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'market impact', 'source': 'industry report', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': ""Bristol Myers Squibb's acquisition of Karuna Therapeutics for $14 billion is a significant investment in the schizophrenia treatment market, with potential sales of $2.8 billion by 2028.""}","[{'aspect_name': 'sales potential', 'description': 'Projected sales figures for schizophrenia treatments', 'comparison': 'KarXT has a projected sales potential of $2.8 billion by 2028.'}]","{'platform': 'industry report', 'date': '2023-10-01', 'sentiment': 'positive', 'discussion_text': 'The acquisition of Karuna Therapeutics is seen as a strong move by Bristol Myers Squibb to enhance their portfolio in the schizophrenia treatment space.'}","{'type': 'positive', 'intensity': 'high'}"
ea5461d0-afde-4ea1-8baf-6bddd33742e7,"New in The Value Science Weekly! ğŸ“°

In this issue, we explore our Insights Article on AI in healthcare in the UAE. Discover how AI is transforming diagnostics and treatment, paving the way for a tech-integrated medical future. ğŸš€

Plus, we cover the value-based pricing and market access of Valbenazine in Japan. 

Your thoughts, drop a comment below?

#HealthcareInnovation #AIinHealthcare #PharmaEconomics #MedicalTechnology #PatientCare ğŸ©ºğŸŒŸğŸ¤–ğŸ’¡",linkedin,2023-12-06T12:35:29.186Z,https://www.linkedin.com/pulse/using-artificial-intelligence-healthcare-united-arab-emirates-3qn6e,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': 'UAE'}","[{'name': 'Valbenazine', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': 'approved'}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'AI in healthcare', 'source': 'Value Science Weekly', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'AI is transforming diagnostics and treatment in healthcare.'}","[{'aspect_name': 'value-based pricing', 'description': 'Pricing strategy based on the value provided by the therapy.', 'comparison': ""Valbenazine's pricing in Japan is based on its efficacy and market access.""}]","{'platform': 'Value Science Weekly', 'date': '2023-10-01', 'sentiment': 'mixed', 'discussion_text': ""Discussion on AI's impact on healthcare and the pricing of Valbenazine.""}","{'type': 'mixed', 'intensity': 'moderate'}"
a27dadaa-c58d-4259-9742-0a2f7e9e5dff,#innovation #management #digitalmarketing #technology #creativity #futurism #startups #marketing #entrepreneurship #money #sustainability #inspiration,linkedin,2024-08-23T01:30:07.894Z,https://www.linkedin.com/pulse/paliperidone-extended-release-tablets-market-report-in-depth-lj09c,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
a3056826-c462-4ea4-9015-d044dd59d13b,Distinction between Aripiprazole and Risperidone,linkedin,2024-03-18T17:34:52.727Z,https://www.linkedin.com/feed/update/urn:li:activity:7175545207818485760?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7175545207818485760%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Aripiprazole', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Risperidone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'comparison', 'source': '', 'timestamp': '', 'insight_text': 'Distinction between Aripiprazole and Risperidone in the context of schizophrenia treatments.'}","[{'aspect_name': 'Efficacy', 'description': 'Comparison of the effectiveness of Aripiprazole and Risperidone in treating schizophrenia.', 'comparison': 'Aripiprazole is often considered to have a lower risk of extrapyramidal symptoms compared to Risperidone.'}, {'aspect_name': 'Safety', 'description': 'Safety profile comparison between Aripiprazole and Risperidone.', 'comparison': 'Risperidone may have a higher incidence of weight gain and metabolic syndrome compared to Aripiprazole.'}, {'aspect_name': 'Mechanism of Action', 'description': 'Differences in how Aripiprazole and Risperidone work in the brain.', 'comparison': 'Aripiprazole acts as a partial agonist at dopamine D2 receptors, while Risperidone is a full antagonist.'}]","{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
f276a970-a029-4c9c-8c18-9d3e4241d070,"ğ‚ğ¥ğ¢ğœğ¤ ğ¡ğğ«ğ ğ“ğ¨ https://lnkd.in/dVDcRXxi ğ ğğ­ ğ°ğğ¥ğ¥-ğ«ğğ¬ğğšğ«ğœğ¡ ğ«ğğ©ğ¨ğ«ğ­ ........................................................................................................................................................#Innovation, #Management, #DigitalMarketing, #Entrepreneurship, #Startups, #Leadership, #BusinessGrowth, #SustainableDevelopment, #EconomicPolicy, #HumanResources, #Marketing, #Technology, #Careers, #SocialMedia, #Entrepreneurâ€‹ #olanzapineconsumptionmarket #olanzapine #consumption #olanzapineconsumptionmarketsize #olanzapineconsumptionmarketshare #olanzapineconsumptionmarketforecast #finance, #investing, #stockmarket, #crypto, #financialfreedom, #personalfinance, #wealth, #trading, #money, #financialliteracy, #economy #lilly #tevapharmaceutical #dr.reddy'slaboratories #apotexinc. #mylanpharmaceuticals #parpharmaceutical #aurobindopharma #torrentpharmaceuticals #jubilantlifesciences #sunpharmaceutical #sandoz #hansohpharmaceutical #watsonpharmaceuticalschangzhou #zhejianglanghuapharmaceuticals",linkedin,2024-08-30T12:00:28.883Z,https://www.linkedin.com/pulse/olanzapine-consumption-market-growth-forecast-6kcrf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Olanzapine', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Lilly', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'discussion', 'source': 'online forum', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
70ac910b-ca4f-487f-9bca-a23200b91c08,"ğ‘¼ğ’ğ’…ğ’†ğ’“ğ’”ğ’•ğ’‚ğ’ğ’…ğ’Šğ’ğ’ˆ ğ‘¨ğ’ğ’•ğ’Šğ’‘ğ’”ğ’šğ’„ğ’‰ğ’ğ’•ğ’Šğ’„ ğ‘«ğ’“ğ’–ğ’ˆğ’”: ğ‘¨ ğ‘ªğ’ğ’ğ’‘ğ’“ğ’†ğ’‰ğ’†ğ’ğ’”ğ’Šğ’—ğ’† ğ‘®ğ’–ğ’Šğ’…ğ’†
ğŸ“š ğƒğ¨ğ§'ğ­ ğ¦ğ¢ğ¬ğ¬ ğ¨ğ®ğ­ ğ¨ğ§ ğ²ğ¨ğ®ğ« ğğƒğ… ğ›ğ«ğ¨ğœğ¡ğ®ğ«ğ: https://lnkd.in/gdqFifaq

Antipsychotic drugs are medications primarily used to manage psychosis, including delusions, hallucinations, paranoia, and disordered thinking, typically associated with conditions like schizophrenia and bipolar disorder. 

They can be classified into two main categories:
âœ” Typical (First-Generation) Antipsychotics: Introduced in the 1950s, these include drugs like haloperidol and chlorpromazine. They primarily target dopamine receptors in the brain, which helps reduce symptoms of psychosis but often come with significant side effects such as sedation, weight gain, and extrapyramidal symptoms (motor control disorders).

âœ” Atypical (Second-Generation) Antipsychotics: Developed later, these include drugs like risperidone, olanzapine, and quetiapine. They target both dopamine and serotonin receptors, often offering improved efficacy for a broader range of symptoms with a lower risk of motor side effects. However, they can still cause significant side effects, including metabolic issues like weight gain and diabetes.

Antipsychotics are crucial in the treatment of severe mental health disorders but require careful monitoring due to their potential side effects and the need for dosage adjustments to find the optimal therapeutic balance. Regular follow-ups with healthcare providers are essential to manage these medications effectively.

#Antipsychotics #MentalHealth #Schizophrenia #BipolarDisorder #Psychiatry #MentalHealthAwareness #MedicationManagement #TypicalAntipsychotics #AtypicalAntipsychotics #MentalHealthTreatment #Psychosis #Healthcare #Wellbeing #MentalIllness #Pharmacology #PsychiatricMedications",linkedin,2024-05-24T18:41:28.620Z,https://www.linkedin.com/feed/update/urn:li:activity:7199841954803638272?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7199841954803638272%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': 'Psychiatry', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Haloperidol', 'type': 'drug', 'indication': 'psychosis, schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Chlorpromazine', 'type': 'drug', 'indication': 'psychosis, schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Risperidone', 'type': 'drug', 'indication': 'psychosis, schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Olanzapine', 'type': 'drug', 'indication': 'psychosis, schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Quetiapine', 'type': 'drug', 'indication': 'psychosis, schizophrenia', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'comparison', 'source': 'comprehensive guide', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'Antipsychotic drugs are crucial in the treatment of severe mental health disorders but require careful monitoring due to their potential side effects and the need for dosage adjustments to find the optimal therapeutic balance.'}","[{'aspect_name': 'Efficacy', 'description': 'Effectiveness of antipsychotic drugs in managing symptoms of schizophrenia.', 'comparison': 'Atypical antipsychotics often offer improved efficacy for a broader range of symptoms compared to typical antipsychotics.'}, {'aspect_name': 'Side Effects', 'description': 'Potential adverse effects associated with antipsychotic medications.', 'comparison': 'Typical antipsychotics are associated with significant side effects such as sedation and extrapyramidal symptoms, while atypical antipsychotics have a lower risk of motor side effects but can cause metabolic issues.'}, {'aspect_name': 'Monitoring Requirements', 'description': 'Need for regular follow-ups and monitoring of patients on antipsychotic medications.', 'comparison': 'Regular follow-ups with healthcare providers are essential for both typical and atypical antipsychotics to manage side effects and dosage adjustments.'}]","{'platform': 'online forum', 'date': '2023-10-01', 'sentiment': 'mixed', 'discussion_text': 'Discussions on the efficacy and safety of antipsychotic medications reveal a mix of experiences, with some patients reporting significant improvements while others face challenging side effects.'}","{'type': 'mixed', 'intensity': 'moderate'}"
4d27e8df-b3a6-4cea-b1d8-266e266fc2b9,#innovation #management #digitalmarketing #technology #creativity #futurism #startups #marketing,linkedin,2024-01-23T06:48:46.726Z,https://www.linkedin.com/pulse/risperidone-market-growth-research-report-jjuuf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
760f4c6c-ce5e-4279-804f-210f39ad4f4e,#innovation #management #digitalmarketing #technology #creativity #futurism #startups #marketing #entrepreneurship #money #sustainability #inspiration,linkedin,2024-08-09T19:00:04.806Z,https://www.linkedin.com/pulse/united-states-aripiprazole-lauroxil-market-application-hfqif,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
15297050-9866-46c8-a669-ee695c015c88,"Another new piece with great colleagues Dong Yun Lee Dong Han Yu (ìœ ë™í•œ) Rae Woong Park about the safety outcomes of 2nd-gen antipsychotics (SGAs) for schizophrenia in South Korea. We comparedÂ the neuropsychiatric, cardiometabolic, and gastrointestinal outcomes between different classes of antipsychotics. 

In our study, parkinsonism was significantly higher with risperidone than with aripiprazole. Cardiometabolic events did not differ significantly between the groups. No difference in adverse events with aripiprazole or risperidone compared to olanzapine, which has well-reported metabolic adverse events, raises interest for further study.

Also, I hope this paper can be a great example using the HIRA CDM of South Korea. 

#Antipsychotics #HIRA #OMOP #CDM  #OHDSI

https://lnkd.in/gjgwuHwN",linkedin,2023-12-10T05:20:30.570Z,https://www.linkedin.com/feed/update/urn:li:activity:7139483999042736128?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7139483999042736128%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Dong Yun Lee', 'specialty': 'Psychiatry', 'affiliation': 'Not specified', 'geographical_region': 'South Korea'}","[{'name': 'Risperidone', 'type': '2nd-generation antipsychotic', 'indication': 'Schizophrenia', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}, {'name': 'Aripiprazole', 'type': '2nd-generation antipsychotic', 'indication': 'Schizophrenia', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}, {'name': 'Olanzapine', 'type': '2nd-generation antipsychotic', 'indication': 'Schizophrenia', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}]","{'name': 'Not applicable', 'type': 'Not applicable', 'indication': 'Not applicable', 'manufacturer': 'Not applicable', 'approval_status': 'Not applicable'}","{'type': 'comparison', 'source': 'clinical study', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'Parkinsonism was significantly higher with risperidone than with aripiprazole. Cardiometabolic events did not differ significantly between the groups. No difference in adverse events with aripiprazole or risperidone compared to olanzapine.'}","[{'aspect_name': 'Parkinsonism', 'description': 'Incidence of parkinsonism as an adverse effect of antipsychotic treatment', 'comparison': 'Higher with risperidone than with aripiprazole.'}, {'aspect_name': 'Cardiometabolic Events', 'description': 'Incidence of cardiometabolic events among different antipsychotics', 'comparison': 'Did not differ significantly between the groups.'}, {'aspect_name': 'Adverse Events', 'description': 'Comparison of adverse events among antipsychotics', 'comparison': 'No difference in adverse events with aripiprazole or risperidone compared to olanzapine.'}]","{'platform': 'Not specified', 'date': '2023-10-01', 'sentiment': 'neutral', 'discussion_text': 'The study raises interest for further research on metabolic adverse events.'}","{'type': 'neutral', 'intensity': 'moderate'}"
08e3c879-915d-4a51-8853-8ee2131e4b0f,"Did you know that just this past year there was a Cochrane Review published on medications for Gambling Disorder?  I didn't until recently, when I was perusing the research as I've seen a significant increase in patients presenting with GD in my private practice.  

Although confidence in conclusions is still low given the lack of high-quality data, the 3 most promising are:

- Naltrexone (yes, that naltrexone)
- Nalmefene (opioid overdose revesal agent, similar to naloxone)
- Olanzapine   

Given that naltrexone and nalmefene tend to be extremely well-tolerated, I'll be interested to see where this research goes over the upcoming years.  Has anyone seen patients try these medications for Gambling Disorder in the real world?  I'd be interested to hear your experiences.

Study: https://buff.ly/3FSYv0E 

#gambling #gamblingaddiction #addiction #pharmacy #psychiatry",linkedin,2022-12-23T20:37:02.870Z,https://www.linkedin.com/feed/update/urn:li:activity:7012154124775432192?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7012154124775432192%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Unnamed Healthcare Professional', 'specialty': 'Psychiatry', 'affiliation': 'Private Practice', 'geographical_region': 'Not specified'}","[{'name': 'Naltrexone', 'type': 'medication', 'indication': 'Gambling Disorder', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}, {'name': 'Nalmefene', 'type': 'medication', 'indication': 'Gambling Disorder', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}, {'name': 'Olanzapine', 'type': 'medication', 'indication': 'Gambling Disorder', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}]","{'name': 'Not applicable', 'type': 'Not applicable', 'indication': 'Not applicable', 'manufacturer': 'Not applicable', 'approval_status': 'Not applicable'}","{'type': 'research', 'source': 'Cochrane Review', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'There was a Cochrane Review published on medications for Gambling Disorder, highlighting Naltrexone, Nalmefene, and Olanzapine as promising treatments.'}","[{'aspect_name': 'tolerability', 'description': 'How well the medications are tolerated by patients', 'comparison': 'Naltrexone and Nalmefene are reported to be extremely well-tolerated.'}]","{'platform': 'online forum', 'date': '2023-10-01', 'sentiment': 'mixed', 'discussion_text': ""Has anyone seen patients try these medications for Gambling Disorder in the real world? I'd be interested to hear your experiences.""}","{'type': 'mixed', 'intensity': 'moderate'}"
8691eccb-4136-4f06-a9a3-139674dc9a72,#innovation #business #company #startup #keyplayers #research #size #share #demand,linkedin,2024-04-09T05:08:47.863Z,https://www.linkedin.com/pulse/paliperidone-market-2024-size-forecast-rabpc,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
ba15b888-96de-4779-87b9-e1e49c952c16,"#innovationÂ #managementÂ #digitalmarketingÂ #technologyÂ #creativityÂ #futurismÂ #startupsÂ #marketing #Size,#Share,#Growth,#Trend,#Forecast,#Future,#Market",linkedin,2024-01-29T17:02:18.452Z,https://www.linkedin.com/pulse/paliperidone-market-size-growth-global-jkdvc,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
e2f18fc9-b64b-4b72-9b66-03060b1aa5ce,#innovation #management #digitalmarketing #technology #creativity #futurism #startups #marketing #entrepreneurship #money #sustainability #inspiration #MarketResearch #BusinessIntelligence #IndustryAnalysis #DataAnalysis #MarketAnalysis #ConsumerInsights #MarketTrends #BusinessStrategy #MarketIntelligence #DataDrivenDecisions #CompetitiveAnalysis #CustomerResearch #MarketingResearch #DataScience #BusinessAnalytics #StrategicInsights #TrendAnalysis #MarketForecast #CustomerBehavior #InsightsDriven **,linkedin,2024-08-01T03:30:34.914Z,https://www.linkedin.com/pulse/united-states-risperidone-api-market-0vutf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
0216c001-ceb0-4b3d-a910-5f52b79e639d,"The US FDA New Drug Approvals in April 2023
- Merckâ€™s Keytruda (pembrolizumab) Receives the US FDAâ€™s Approval as 1L Treatment of Locally Advanced or Metastatic Urothelial Cancer
- IntelGenxâ€™s Rizafilm Receives the US FDAâ€™s Approval for the Treatment of Acute Migraine
- Gamida Cellâ€™s Omisirge (omidubicel-onlv) Receives the US FDAâ€™s Approval for Hematologic Malignancies
- Genentechâ€™s Polivy (polatuzumab vedotin) Receives the US FDAâ€™s Approval for Diffuse Large B-cell Lymphoma
- AbbVieâ€™s Qulipta (atogepant) Receives the US FDA's Approval for Expanded Indication in Adults with Chronic Migraine
- Vertexâ€™s Trikafta Receives the US FDAâ€™s Approval for the Treatment of Children with Cystic Fibrosis Aged 2 Through 5 Years
- Biogen and Ionis Receive the US FDAâ€™s Approval of Qalsody (tofersen) for the Treatment of Amyotrophic Lateral Sclerosis
- Otsuka and Lundbeckâ€™s Abilify Asimtufii (aripiprazole) Receive the US FDAâ€™s Approval as First Long-Acting Injectable for Schizophrenia or Bipolar I Disorder
- Seres Therapeutics and NestlÃ© Health Science Receive the US FDAâ€™s Approval of VOWST for the Prevention of Recurrence of C. Difficile Infection
- Teva and MedinCell Receive the US FDAâ€™s Approval of Uzedy (risperidone) Extended-Release Injectable Suspension for Schizophrenia

You can read more at:https://lnkd.in/d9aTUrNq
#fda 
#health #science #Newdrug #Approval #April #2023 #CliniResource",linkedin,2023-05-17T13:37:57.454Z,https://www.linkedin.com/pulse/us-fda-new-drug-approvals-april-2023-the-pharmashots,"{'name': '', 'specialty': 'Psychiatry', 'affiliation': '', 'geographical_region': 'US'}","[{'name': 'Abilify Asimtufii', 'type': 'drug', 'indication': 'Schizophrenia or Bipolar I Disorder', 'manufacturer': 'Otsuka and Lundbeck', 'approval_status': 'Approved'}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'approval', 'source': 'US FDA', 'timestamp': '2023-04-01T00:00:00Z', 'insight_text': 'Abilify Asimtufii (aripiprazole) has received US FDA approval as the first long-acting injectable for schizophrenia or bipolar I disorder.'}","[{'aspect_name': 'Efficacy', 'description': 'Effectiveness of the drug in treating schizophrenia symptoms.', 'comparison': 'Abilify Asimtufii is a long-acting injectable formulation that may improve adherence compared to oral formulations.'}, {'aspect_name': 'Safety', 'description': 'Profile of side effects associated with the drug.', 'comparison': 'Long-acting injectables like Abilify Asimtufii may have a different side effect profile compared to oral medications.'}, {'aspect_name': 'Market Impact', 'description': 'Potential influence on the market for schizophrenia treatments.', 'comparison': 'The approval of Abilify Asimtufii may increase competition in the long-acting injectable market for schizophrenia.'}]","{'platform': 'online forum', 'date': '2023-04-01', 'sentiment': 'mixed', 'discussion_text': 'Discussions around the approval of Abilify Asimtufii highlight both excitement for a new treatment option and concerns about long-term safety.'}","{'type': 'mixed', 'intensity': 'moderate'}"
32931af4-c836-48fb-8496-185a01dbd028,ğ‚ğ¥ğ¢ğœğ¤ ğ¡ğğ«ğ ğ“ğ¨ https://lnkd.in/e2Ega5KH ğ ğğ­ ğ°ğğ¥ğ¥-ğ«ğğ¬ğğšğ«ğœğ¡ ğ«ğğ©ğ¨ğ«ğ­ #websiteandsoftwarelocalizationservicesmarket #website #and #software #localization #services #websiteandsoftwarelocalizationservicesmarketsizeÂ #websiteandsoftwarelocalizationservicesmarketshare #websiteandsoftwarelocalizationservicesmarketforecastÂ #smes #largeenterprises #machinetranslation #expertstranslation #rws # #languagelinesolutions # #keywordstudios # #lionbridge # #lyunosdigroup # #welocalizeinc. # #acoladgroup # #hogarthworldwide # #stargroup # #amnlanguageservices # #cyracom # #pacteraedge # #ptsgi # #unitedlanguagegroup # #ubiqus,linkedin,2024-09-13T12:30:14.949Z,https://www.linkedin.com/pulse/website-software-localization-services-market-applicationmachine-onr7e,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
0e508472-55fa-4341-ae5c-a2af030fdd56,#innovation #management #digitalmarketing #technology #creativity #futurism #startups #marketing #entrepreneurship #money #sustainability #inspiration,linkedin,2024-07-24T03:00:06.966Z,https://www.linkedin.com/pulse/pharmaceutical-grade-paliperidone-market-arssc,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
2ab18398-4ff5-401d-ab20-59cfdb055707,"Paliperidone is the primary active metabolite of risperidone, which
has been used in the treatment of schizophrenia since the 1990s. Paliperidoneâ€™s therapeutic effect is mediated through antagonist activity at D2- and 5-HT2A receptors.",linkedin,2024-01-28T09:02:32.870Z,https://www.linkedin.com/feed/update/urn:li:activity:7157296882233294848?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7157296882233294848%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Paliperidone', 'type': 'drug', 'indication': 'schizophrenia', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
d757bb14-22bb-4307-b251-5165a53f84b6,"Today, the Federal Circuit in Janssen v. Teva vacated and remanded the district court's conclusion of nonobviousness and affirmed the conclusion that indefiniteness of the claims was not proven.  The Court noted that if on remand all claims were found to be obvious, it would really matter whether they were definite. 

The product involved in the suit was Janssen's Invega Sustenna, an extended release intramuscular injectable of paliperidone palmitate, indicated for the treatment of schizophrenia in adults. The court spent about 25 pages highlighting what it perceived to be errors in the district court's nonobviouness analysis.  

In a short post, it would be difficult to go through perceived error by perceived error. Something that jumped out at me, however, was the Federal Ciruit's emphasis that claims at issue did not always match up with the district court's nonobviousness analysis.  

Hamlet said something like the Play is the thing.  In U.S. patent law, the claim is the thing.  

Seems to me this case, however it comes out on remand, and it is certainly a worthy read, underlies the importance of the emphasis my law partner, Michelle O'Brien of The Marbury Law Group, PLLC and I place on the importance of Sanofi v. Watson-type claims firmly founded on matching claims with the results of Phase III clinical trials. ğŸ˜ 

Not legal advice, no attorney client relationship, educational purposes only, does not reflect past, present, or future views of clients of The Marbury Law Group, PLLC, and liability for any errors or omissions is disclaimed.",linkedin,2024-04-01T19:05:11.893Z,https://www.linkedin.com/feed/update/urn:li:activity:7180641367566565378?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7180641367566565378%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': ""Michelle O'Brien"", 'specialty': 'Patent Law', 'affiliation': 'The Marbury Law Group, PLLC', 'geographical_region': 'United States'}","[{'name': 'Invega Sustenna', 'type': 'injectable', 'indication': 'schizophrenia', 'manufacturer': 'Janssen', 'approval_status': 'approved'}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'legal analysis', 'source': 'court ruling', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': ""The Federal Circuit emphasized that claims at issue did not always match up with the district court's nonobviousness analysis.""}","[{'aspect_name': 'nonobviousness', 'description': 'The analysis of whether the claims of a patent are obvious based on prior art and existing knowledge.', 'comparison': ""The Federal Circuit vacated the district court's conclusion of nonobviousness, indicating potential errors in the analysis.""}, {'aspect_name': 'definiteness', 'description': 'The clarity and precision of the claims in a patent.', 'comparison': 'The court affirmed that the indefiniteness of the claims was not proven.'}]","{'platform': 'legal commentary', 'date': '2023-10-01', 'sentiment': 'neutral', 'discussion_text': 'The case highlights the importance of matching claims with the results of Phase III clinical trials.'}","{'type': 'neutral', 'intensity': 'moderate'}"
f24027ad-538c-4e99-891e-11c6f5246685,Xanomeline is a dual M1/M4 preferring muscarinic receptor agonist with no direct D2 dopamine receptor blocking activity. KarXT combines xanomeline with the peripheral muscarinic receptor antagonist trospium chloride with the goal of reducing adverse events due to xanomeline-related peripheral muscarinic receptor activation.,linkedin,2024-05-02T00:13:15.425Z,https://www.linkedin.com/feed/update/urn:li:activity:7191590529086709760?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7191590529086709760%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Xanomeline', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'KarXT', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
7c0e79f0-1cab-4809-a163-9df9f9ba24d8,"Elated to share the publication of our research entitled ""Paliperidone Palmitate Loaded Zeinâ€‘Maltodextrin Nanocomplex:
Fabrication, characterization, and In Vitro Release ""in Journal of Pharmaceutical Innovation, Springer (https://lnkd.in/dCvW8sBE).

Massive gratitude to my mentor, Prof. Vaishali Londhe, for her constant support and guidance!

Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKMâ€™s NMIMS

#Vaishali Londhe's Lab
#Journal of Pharmaceutical Innovation #Springer  
#nanocomplex #technology  #nanotechnology #drugdelivery #research  #opportunity #gratitude",linkedin,2023-03-03T05:12:42.277Z,https://www.linkedin.com/feed/update/urn:li:activity:7037288656780312576?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7037288656780312576%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Prof. Vaishali Londhe', 'specialty': 'Pharmaceutical Sciences', 'affiliation': 'Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKMâ€™s NMIMS', 'geographical_region': 'India'}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
4ea37160-e1d3-4dac-998d-48f3815d0eda,"This needs to be shared, needs to be read, and most importantly heard. 

Sertraline- Zoloft
Venlafaxine- Effexor
Citalopram- Celexa
Mirtazapine-Remeron
Fluoxetine- Prozac
Duloxetine- Cymbalta
Seroquel- Quetiapine
Lamictal- Lamotrigine
Lexapro- Escitalopram
Wellbutrin- Bupropion
Lorazepam- Ativan
Klonopin- Clonazepam
Abilify - aripiprazole 
Tegrotal - carabamezipine
Buspar - buspirone

You may know what these tablets are or know a loved one who takes them, but in case you don't, I will fill you in. That medication allows people to deal with a normal day to day life. Although most days it leaves them tired, spaced out, emotionless, or even super emotional.

Crazy right? Why would anyone want to feel like that?

Well this is why!!

You see, some people suffer from severe depression and anxiety. 
In their brain it doesn't sit right, something seems different. They notice little differences that other people wouldn't. Most days they wake up sick and feel sleepless. 

They consistently overthink every situation.
Was a comment about them; was it a joke? 
Was that person supposed to laugh? 
Or did they mean it? 
Are they being nice? 
Are they talking about them? 
Do they talk about them? 
They then think, I bet they donâ€™t like me really. 

They say sorry all the time. They feel like they annoy everyone. 
And for all those questions they will spend hours trying to answer. Let it all build up in their mind, until it sends them to tears...... it's mental that they see things that way. 

It's not only mental changes, but physical changes. They don't eat a lot or they eat way too much. Insomnia, up all night answering questions to situations that don't even exist, or sleep too much and waste half their day still feeling tired. 

They still smile and they have every excuse for when you ask why.
But the tablets can help them. Because they know when they start to feel this way or think this way, they need help. 

They know that when their behavior starts to change, They need guidance.  And they understand that they don't need to be ashamed. They don't need to be understood. They just need to be accepted. Everyone is fighting a battle and sometimes you need to be kinder. 

So I may just be another person who's talking about mental health....

Living with this illness is hard, but trying to understand it, is even harder. Itâ€™s also 100 times harder if they have another condition on top of this.

Don't suffer in silence.

Mental health is just as important as physical health.

Be part of the healing.ğŸ’™
Be understanding.ğŸ’™
Be kind. ğŸ’™

ğŸ’™ Copied and pasted.ğŸ’™  

Sometimes donâ€™t even try to understand, just simply love that person, support them, and be there when they need you. Some people in my life have truly mastered this, and for you I will forever be grateful!",linkedin,2023-10-05T17:40:10.777Z,https://www.linkedin.com/feed/update/urn:li:activity:7115752543992832001?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7115752543992832001%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Sertraline', 'type': 'drug', 'indication': 'depression, anxiety', 'manufacturer': '', 'approval_status': ''}, {'name': 'Venlafaxine', 'type': 'drug', 'indication': 'depression, anxiety', 'manufacturer': '', 'approval_status': ''}, {'name': 'Citalopram', 'type': 'drug', 'indication': 'depression', 'manufacturer': '', 'approval_status': ''}, {'name': 'Mirtazapine', 'type': 'drug', 'indication': 'depression', 'manufacturer': '', 'approval_status': ''}, {'name': 'Fluoxetine', 'type': 'drug', 'indication': 'depression', 'manufacturer': '', 'approval_status': ''}, {'name': 'Duloxetine', 'type': 'drug', 'indication': 'depression, anxiety', 'manufacturer': '', 'approval_status': ''}, {'name': 'Seroquel', 'type': 'drug', 'indication': 'schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Lamictal', 'type': 'drug', 'indication': 'bipolar disorder', 'manufacturer': '', 'approval_status': ''}, {'name': 'Lexapro', 'type': 'drug', 'indication': 'depression, anxiety', 'manufacturer': '', 'approval_status': ''}, {'name': 'Wellbutrin', 'type': 'drug', 'indication': 'depression', 'manufacturer': '', 'approval_status': ''}, {'name': 'Lorazepam', 'type': 'drug', 'indication': 'anxiety', 'manufacturer': '', 'approval_status': ''}, {'name': 'Klonopin', 'type': 'drug', 'indication': 'anxiety', 'manufacturer': '', 'approval_status': ''}, {'name': 'Abilify', 'type': 'drug', 'indication': 'schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Tegretal', 'type': 'drug', 'indication': 'seizures, bipolar disorder', 'manufacturer': '', 'approval_status': ''}, {'name': 'Buspar', 'type': 'drug', 'indication': 'anxiety', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'discussion', 'source': 'online forum', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'Living with mental health issues like schizophrenia is challenging, and understanding the treatments available is crucial.'}","[{'aspect_name': 'Efficacy', 'description': 'The effectiveness of the drugs in treating schizophrenia and related symptoms.', 'comparison': 'Seroquel and Abilify are both effective in managing schizophrenia symptoms, but they may have different side effect profiles.'}, {'aspect_name': 'Safety', 'description': 'The safety profile of the drugs, including side effects and contraindications.', 'comparison': 'Seroquel may cause sedation, while Abilify is less sedating but may lead to akathisia.'}, {'aspect_name': 'Market Impact', 'description': 'The market presence and acceptance of the drugs in treating schizophrenia.', 'comparison': 'Abilify has a significant market share due to its efficacy and safety profile, while Seroquel is also widely used but may face competition from newer agents.'}]","{'platform': 'online forum', 'date': '2023-10-01', 'sentiment': 'mixed', 'discussion_text': 'There are many discussions about the side effects of schizophrenia medications and their impact on daily life.'}","{'type': 'mixed', 'intensity': 'moderate'}"
1b292f6a-ac7e-4fc1-bd34-d0205e7fb435,Long Acting Injectable Risperidone [Risperidone Injectable],linkedin,2024-06-26T01:35:26.639Z,https://www.linkedin.com/feed/update/urn:li:activity:7211542544705310720?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7211542544705310720%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Long Acting Injectable Risperidone', 'type': 'injectable', 'indication': 'schizophrenia', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
8d454a20-9853-416a-888b-4a7298b45add,"I am thrilled to announce that I have recently assumed the role of Executive Director of US Marketing for the launch of KarXT at BMS.
The past few months have undoubtedly been the most memorable in my professional career, representing one of those 'once in a lifetime' moments. I had the privilege of being part of the core acquisition team for the Karuna deal and have been fortunate enough to continue working on the US launch of KarXT in Schizpophrenia.
Now, I have with the opportunity to shape one of the most anticipated launches alongside an incredibly passionate and talented team.
#BMSEmployee",linkedin,2024-05-24T12:21:47.855Z,https://www.linkedin.com/feed/update/urn:li:activity:7199746405349892096?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7199746405349892096%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Executive Director of US Marketing', 'specialty': 'Marketing', 'affiliation': 'BMS', 'geographical_region': 'US'}","[{'name': 'KarXT', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Karuna Therapeutics', 'approval_status': 'Pending'}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'launch announcement', 'source': 'personal announcement', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'I have recently assumed the role of Executive Director of US Marketing for the launch of KarXT at BMS.'}",[],"{'platform': 'social media', 'date': '2023-10-01', 'sentiment': 'positive', 'discussion_text': 'I am thrilled to announce the launch of KarXT, representing a significant moment in my career.'}","{'type': 'positive', 'intensity': 'high'}"
c3bd0a62-91cf-4f61-9612-37e37167eb8c,"Excited to share our latest research paper titled ""Simultaneous determiantion of aripiprazole and escitalopram oxalate by HPLC"" has been successfully published in Web of Science, Scopus active journal ""Journal of Chemical Metrology"". Read the full paper at",linkedin,2023-11-04T10:12:57.713Z,https://www.linkedin.com/feed/update/urn:li:activity:7126511633933213696?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7126511633933213696%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
d8fcf189-bc95-4bd1-8803-56075e05a781,,linkedin,2023-08-03T20:09:10.009Z,https://www.linkedin.com/pulse/paliperidone-palmitate-reagent-market-size,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
23c6a517-9e53-43cb-8119-e1658c9b7db8,"ğŸ“ƒScientific paper: Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical Setting

Abstract:

OBJECTIVE: To evaluate the long-term efficacy and safety of three-monthly paliperidone palmitate (PP3M) in Asian patients with stable schizophrenia in a naturalistic setting.

METHODS: Asian patients recruited between May 2016 and March 2018 from the prospective, single-arm, non-randomized, open-label, multi-national REMISSIO study were analyzed.

Patients received PP3M over 12 months following â‰¥ 4 months of treatment with one-monthly paliperidone palmitate.

The primary efficacy endpoint was the proportion of patients who achieved symptomatic remission.

Other endpoints were changes in Positive and Negative Syndrome Scale (PANSS) and Personal and Social Performance (PSP) total scores, hospitalization rates, and safety.

RESULTS: A total of 71 patients (23.3%) were Asian (South Korea 33, Malaysia 21, Taiwan 17); 95.8% of patients completed the study.

At LOCF, 71% of Asian patients achieved symptomatic remission compared to the overall population (n = 172/303, 56.8%).

Improvements in mean (standard deviation) PANSS and PSP total scores from baseline to LOCF in Asian patients and overall population were clinically significant.

A lower proportion of Asian patients had â‰¥ 1 psychiatric hospitalization after PP3M treatment (n = 1/70, 1.4%) than during the 12 months before (n = 12/70, 17.1%); compared with patients in the overall population after (n = 8/303, 2.6%) and before PP3M treatment (n = 37/303, 12.2%).

The overall incidence of treatment-emergent adverse events across A...

 Discover the rest of the scientific article on es/iode â¡ï¸https://etcse.fr/Ncap",linkedin,2023-12-24T13:16:08.853Z,https://www.linkedin.com/feed/update/urn:li:activity:7144677127395704832?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7144677127395704832%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': 'Psychiatry', 'affiliation': '', 'geographical_region': 'Asia'}","[{'name': 'Paliperidone Palmitate 3-month Formulation', 'type': 'injectable drug', 'indication': 'Stable Schizophrenia', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'efficacy and safety', 'source': 'REMISSIO Study', 'timestamp': '2018-03-01T00:00:00Z', 'insight_text': '71% of Asian patients achieved symptomatic remission with PP3M compared to 56.8% in the overall population.'}","[{'aspect_name': 'symptomatic remission', 'description': 'Proportion of patients achieving symptomatic remission after treatment', 'comparison': '71% of Asian patients achieved symptomatic remission with PP3M compared to 56.8% in the overall population.'}, {'aspect_name': 'hospitalization rates', 'description': 'Comparison of psychiatric hospitalization rates before and after treatment', 'comparison': '1.4% of Asian patients had psychiatric hospitalization after PP3M treatment compared to 17.1% before.'}]","{'platform': 'Scientific paper', 'date': '2018-03-01', 'sentiment': 'positive', 'discussion_text': 'The study indicates significant improvements in PANSS and PSP scores, suggesting the efficacy of PP3M in Asian patients.'}","{'type': 'positive', 'intensity': 'moderate'}"
7d5e4468-7fc4-45ca-8a8d-026cb955e281,#BusinessGrowth #StartupLife #EntrepreneurMindset #Innovation #BusinessStrategy #SMEs #DigitalMarketing #Networking #ECommerce #B2B #innovationandcreativity #innovation #creativity #business #technology #tech #industry,linkedin,2024-07-16T09:30:09.546Z,https://www.linkedin.com/pulse/north-america-olanzapine-api-market-application-te6zf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
4640dd9b-7b8c-43b8-8717-5ffa61823014,ğ‚ğ¥ğ¢ğœğ¤ ğ¡ğğ«ğ ğ“ğ¨ https://lnkd.in/gnx8cpzz ğ ğğ­ ğ°ğğ¥ğ¥-ğ«ğğ¬ğğšğ«ğœğ¡ ğ«ğğ©ğ¨ğ«ğ­ #aripiprazoleoralsolutionmarket #aripiprazole #oral #solution #aripiprazoleoralsolutionmarketsizeÂ #aripiprazoleoralsolutionmarketshare #aripiprazoleoralsolutionmarketforecast #originaldrugs #genericdrugs #hospital #psychologyclinic #other#otsuka #https://lnkd.in/giCfDDG2. #https://lnkd.in/gHGYubjU. #https://lnkd.in/gAik_gGg. #wantepharmaceutical #brillpharmalimited #apotex #amnealpharmaceuticalsllc #inceptapharmaceuticalsltd,linkedin,2024-08-16T17:15:06.389Z,https://www.linkedin.com/pulse/global-aripiprazole-oral-solution-market-application-xwc9c,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Aripiprazole Oral Solution', 'type': 'oral solution', 'indication': 'Schizophrenia', 'manufacturer': 'Otsuka', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'market analysis', 'source': 'LinkedIn', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'The aripiprazole oral solution market is expected to grow, with increasing demand for both original and generic drugs.'}","[{'aspect_name': 'Efficacy', 'description': 'Effectiveness of the drug in treating schizophrenia symptoms', 'comparison': 'Aripiprazole is known for its efficacy in managing schizophrenia symptoms compared to other antipsychotics.'}, {'aspect_name': 'Safety', 'description': 'Profile of side effects and safety concerns', 'comparison': 'Aripiprazole has a favorable safety profile with fewer side effects compared to traditional antipsychotics.'}, {'aspect_name': 'Market Impact', 'description': 'Influence on the market and competition', 'comparison': 'The entry of generic versions of aripiprazole is expected to impact market share significantly.'}]","{'platform': 'LinkedIn', 'date': '2023-10-01', 'sentiment': 'positive', 'discussion_text': 'Discussions around aripiprazole highlight its effectiveness and safety, with many professionals advocating for its use in schizophrenia treatment.'}","{'type': 'positive', 'intensity': 'moderate'}"
872f545d-b9f6-4e9b-8981-1ad2b7ff218a,#innovation #management #digitalmarketing #technology #creativity #futurism #startups #marketing #entrepreneurship #money #sustainability #inspiration,linkedin,2024-07-17T17:30:30.971Z,https://www.linkedin.com/pulse/north-america-aripiprazole-api-market-application-sqeuf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
4c00ed96-f15d-4381-98bb-55749fb38e28,#paliperidonemarket #paliperidone #paliperidonemarketsize #paliperidonemarketshare #paliperidonemarketforecast #innovation #digitaltransformation #business #marketing #womeninbusiness #networking #BusinessDevelopment #LeadershipDevelopment #RemoteWork #DigitalMarketing #AI #FutureOfWork #Entrepreneurship #SalesTips #DataAnalytics #PersonalBranding #CareerAdvice #DiversityandInclusion #TechTrends #HR #WorkLifeBalance #Sustainability #FinancialServices #Healthcare,linkedin,2024-06-12T12:30:04.212Z,https://www.linkedin.com/pulse/adult-pediatric-vaccines-market-size-emerging-growth-ibvvf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
0c8399fc-2e04-445a-b0de-cd2374ce414a,"Market Dynamics and Future Trends in the Global Paliperidone API Market Sector forecasted for period from 2024 to 2031
#PaliperidoneAPIMarket
#PaliperidoneAPIMarketSize
#PaliperidoneAPIMarketResearchReport
#PaliperidoneAPIMarketCAGR
#PaliperidoneAPIMarketGrowth
#Innovation
#Management
#DigitalMarketing
#Technology
#Creativity
#Futurism
#Startups
#Marketing",linkedin,2024-08-23T09:00:03.941Z,https://www.linkedin.com/pulse/market-dynamics-future-trends-global-paliperidone-api-sector-8o0bf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
36acd708-d300-4299-8019-082371500f26,"ğ™ğ™ğ˜¼, ğ™‰ğ™šğ™¬ ğ™…ğ™šğ™§ğ™¨ğ™šğ™®- The Global Risperidone Market: 2023-2030, an extraordinary journey of growth and transformation. Cutting-edge tech, dynamic trends, and boundless opportunities will reshape industries and revolutionize our lives. ğ—šğ—˜ğ—§ | ğ—¦ğ—®ğ—ºğ—½ğ—¹ğ—² ğ—¢ğ—³ ğ—§ğ—µğ—² ğ—¥ğ—²ğ—½ğ—¼ğ—¿ğ˜ >> https://lnkd.in/dfNGUqTt",linkedin,2023-09-25T09:40:09.085Z,https://www.linkedin.com/pulse/risperidone-market-size-trends-growth-scope-2030,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': 'USA, New Jersey'}",[],"{'name': '', 'type': '', 'indication': 'schizophrenia', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
404707fd-748d-423d-bab3-4ca204403bfd,"#MarketResearch, #IndustryAnalysis, #MarketTrends, #BusinessInsights, #MarketStudy, #CompetitiveAnalysis, #MarketGrowth, #ConsumerBehavior, #BusinessStrategy, #ResearchReport",linkedin,2024-07-20T08:30:08.330Z,https://www.linkedin.com/pulse/north-america-pharmaceutical-grade-paliperidone-market-vgsif,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
9ef31ceb-7102-4c12-9473-7e0f7924cdeb,#innovation #management #digitalmarketing #technology #creativity #futurism #startups #marketing #entrepreneurship #money #sustainability #inspiration,linkedin,2024-09-13T05:30:08.731Z,https://www.linkedin.com/pulse/north-america-high-pressure-booster-compressor-market-hjnrf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
03fdefcd-6651-47d4-baec-5937377072bf,"KarXT refers to a combo of xanomeline and trospium for Schizophrenia treatment, developed by Karuna Therapeutics. Instead of targeting dopamine receptors for Schizophrenia treatment, Xanomeline was previously developed as an agonist of muscarinic acetylcholine receptors (i.e. M1 & M4) to regulate the dopaminergic and glutamatergic circuits in the brain for Schizophrenia treatment and offered promising improvements. To mitigate the side effects caused by unwanted binding to the receptors located in the peripheral region, combination with trospium, a cholinergic muscarinic antagonist, is designed, giving KarXT. In the phase 3 clinical trial, KarXT showed great efficacy and good safety and tolerability, potentially becoming the best-in-class drug in the near future for Schizophrenia treatment. Meantime, it also shows promises in treating other CNS diseases. Recently, BMS acquired Karuna Therapeutics for $14B, and this new strategic merger deal is regarded as part of its strategy to bolster its neuroscience portfolio.",linkedin,2024-01-07T02:48:04.356Z,https://www.linkedin.com/feed/update/urn:li:activity:7149592497277579264?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7149592497277579264%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': 'Psychiatry', 'affiliation': '', 'geographical_region': ''}","[{'name': 'KarXT', 'type': 'combination therapy', 'indication': 'Schizophrenia', 'manufacturer': 'Karuna Therapeutics', 'approval_status': 'Phase 3 clinical trial'}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'efficacy and safety', 'source': 'clinical trial', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'KarXT showed great efficacy and good safety and tolerability in the phase 3 clinical trial.'}","[{'aspect_name': 'mechanism of action', 'description': 'KarXT combines xanomeline, an agonist of muscarinic acetylcholine receptors, with trospium, a cholinergic muscarinic antagonist.', 'comparison': 'Unlike traditional schizophrenia treatments that target dopamine receptors, KarXT regulates dopaminergic and glutamatergic circuits.'}, {'aspect_name': 'market impact', 'description': 'BMS acquired Karuna Therapeutics for $14B as part of its strategy to bolster its neuroscience portfolio.', 'comparison': 'This acquisition indicates a strong market interest in KarXT as a potential best-in-class drug for schizophrenia.'}]","{'platform': 'clinical trial report', 'date': '2023-10-01', 'sentiment': 'positive', 'discussion_text': ""KarXT's performance in clinical trials has generated positive discussions regarding its potential as a leading treatment for schizophrenia.""}","{'type': 'positive', 'intensity': 'high'}"
c47aac37-88ed-4d5c-ba48-f6708c5c6db0,"Market Summaryâ€“Tata Consultancy Planning Reorganization of Top Leadership, Aditya Birla Capital To Sell Entire Stake In Insurance Brokerage Unit, HDFC To Raise Rs 57k Crore Via Bonds, Govt hikes customs duty on importÂ of X-Ray Machinr , Manipal Buys Emamiâ€™s AMRI Hospitals for INR24b, S&P keeps India's economic growth forecast unchanged at 6% in FY24, RBI Extends Timeline For PA License Application on PAYTM, RBI Extends Timeline For PA License Application on PAYTM, Mahindra Logistics and Ascendas-Firstspace announces launch of one million sq. ft. warehouse park in Pune. Warburg Pincus Seeks $35m in Kalyan Jewellers Placement

TCSâ€“Company is planning to reorganize top leadership roles, including chief technology officer and chief operating officer, the Economic Times reports-positive

HDFCâ€“Company approved raising Rs57000cr via bonds in tranches and approved increase in borrowing power to Rs6.5tn from Rs6tnâ€“Positive

Aditya Birla Capital-Company will offload its entire 50.002% stake in subsidiary Aditya Birla Insurance Brokers at an enterprise value of Rs 455 crore. The company's board approved the transfer of 25.65 lakh shares or 50% stake in Aditya Birla Insurance Brokers, to Edme Services Pvt. Ltd., a part of the Samara Capital Group and an affiliate of Samara Alternate Investment Fundâ€“positive

Kalyan Jewellersâ€“Warburg Pincus, offers 2.62cr shares in Kalyan JewellersÂ via block deal with a floor price of Rs110 per share, a 7.4% discount to the last close of Rs118.75â€“Buying opportunity.

Nestle India's-Board To Consider Interim Dividend On April 12 The record date for the dividend will be April 21, 2023, same as the final dividend for year 2022.

Lupin Ltdâ€“Company secured USFDA tentative approval for valbenazine capsules. Valbenazine, a generic equivalent of Neurocrine's Ingrezza, is indicated for the treatment of tardive dyskinesia, or the uncontrollable movement of the face, tongue, or other body partsâ€“positive

Radico Khaitanâ€“Company announced today that 1965 Spirit of Victory rum joins the millionaire club becoming the Company's 7th brand to achieve the million case mark. - Positive

Heritage Foodsâ€“Company announced the launch of its new range of Buttermilk products under the brand name 'A-One' and a new range of milkshakes in the easy-to carry and single serve carton boxesâ€“positive

BLS International-Company has signed an agreement with the Polish Embassy in Manila to provide visa outsourcing services. Under this agreement, the company will be processing 20,000 applications annually and opening offices in Manila and Cebu-Positive

India Pesticidesâ€“Company has received Technical Equivalence (TEQ) certification in the European Union (EU) for its newly commissioned herbicide technical product. This certification will bolster the company's export revenue and contribute to increased foreign exchange earnings for the countryâ€“positive
Â 
#marketsummary  #sharemarketnews #india #business #entrepreneur #money #share #bitcoin #forex #investment #wealth",linkedin,2023-03-28T04:37:52.976Z,https://www.linkedin.com/feed/update/urn:li:activity:7046339590256746497?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7046339590256746497%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
eaf00185-93a7-420f-b232-31ed32e728ca,"The combination of AI + traditional simulation tools is powerful ğŸ’ª 

Here's an example of what we're building at Persist

1/ First we ask our AI model to predict what process parameters can help build a 60 day Risperidone injectable

2/ Our model predicts the rate of drug release as well as formulation parameters

3/ These predictions then feed into classical in vivo simulations used in pharmacokinetic analyses

The result is a system that can target a desired QTPP 

And then validate with our robotic lab (which carries out the experiments)

Super cool huh?",linkedin,2024-07-26T16:39:06.716Z,https://www.linkedin.com/feed/update/urn:li:activity:7222641596159213568?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7222641596159213568%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Risperidone', 'type': 'injectable', 'indication': 'schizophrenia', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
dd5d301e-a86c-4081-933b-a59c5ec27d76,"#mentalhealth #schizophrenia #clozapine #survival
From the abstract of this study, the use of clozapine had a protective effect on survival when compared to olanzapine, risperidone, quetiapine, and ziprasidone.",linkedin,2024-07-21T23:07:18.902Z,https://www.linkedin.com/feed/update/urn:li:activity:7220927351340064769?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7220927351340064769%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': 'Psychiatry', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Clozapine', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Olanzapine', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Risperidone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Quetiapine', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Ziprasidone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'comparison', 'source': 'study abstract', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'The use of clozapine had a protective effect on survival when compared to olanzapine, risperidone, quetiapine, and ziprasidone.'}","[{'aspect_name': 'Survival', 'description': 'The effect of different antipsychotic medications on patient survival rates.', 'comparison': 'Clozapine shows a protective effect on survival compared to olanzapine, risperidone, quetiapine, and ziprasidone.'}]","{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': 'positive', 'intensity': 'moderate'}"
e330aa62-ee8c-437f-be21-18d10e9f9f27,"Medications for psychosis such as schizophrenia or bipolar disorders with psychotic symptoms are divided into two group group 1 considered as generation 1 typical antipsychotic medications with more and huge side effects or group 2 which considered as generation 2 antipsychotic new medications with less sude effects
First-generation typical or conventional antipsychotics such as Chlorpromazine, Fluphenazine, Perphenazine,Thioridazine and Haloperidol 
Second-generation or atypical antipsychotics Such as Aripiprazole, Aripiprazole lauroxil, Lumateperonee,Lurasidone 
#mentalwellbeing",linkedin,2024-06-27T14:31:52.147Z,https://www.linkedin.com/feed/update/urn:li:activity:7212100326353514497?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7212100326353514497%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': 'Psychiatry', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Chlorpromazine', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Fluphenazine', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Perphenazine', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Thioridazine', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Haloperidol', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Aripiprazole', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Aripiprazole lauroxil', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Lumateperone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Lurasidone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'comparison', 'source': 'online discussion', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'First-generation antipsychotics have more side effects compared to second-generation antipsychotics.'}","[{'aspect_name': 'Side Effects', 'description': 'Comparison of side effects between first-generation and second-generation antipsychotics.', 'comparison': 'First-generation antipsychotics have more and severe side effects, while second-generation antipsychotics have less severe side effects.'}]","{'platform': 'online forum', 'date': '2023-10-01', 'sentiment': 'mixed', 'discussion_text': 'There are ongoing discussions about the efficacy and safety of both generations of antipsychotics.'}","{'type': 'mixed', 'intensity': 'moderate'}"
529ad816-6cd3-45b3-9730-a2fdf1da78bd,Olazapine helps to reduce chemotherapy induced nausea and vomiting,linkedin,2024-08-06T16:58:47.436Z,https://www.linkedin.com/feed/update/urn:li:activity:7226632814979387392?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7226632814979387392%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Olazapine', 'type': 'drug', 'indication': 'schizophrenia', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
f9f642bd-84e6-4e9d-a656-7b6b5c99274f,ğ‚ğ¥ğ¢ğœğ¤ ğ¡ğğ«ğ ğ“ğ¨ https://lnkd.in/gPkSAQjk ğ ğğ­ ğ°ğğ¥ğ¥-ğ«ğğ¬ğğšğ«ğœğ¡ ğ«ğğ©ğ¨ğ«ğ­ #paliperidoneextendedreleasetabletsmarket #paliperidone #extended #release #tablets #paliperidoneextendedreleasetabletsmarketsizeÂ #paliperidoneextendedreleasetabletsmarketshare #paliperidoneextendedreleasetabletsmarketforecastÂ #hospital #psychiatrichospital #other #3mg #6mg #janssenpharmaceutical # #cspcouyipharmaceuticalco. # #ltd. # #hansohpharmaceuticalgroupcompanylimited # #shenzhenkangzhebiotechnologyco. # #ltd. # #haiscopharmaceuticalgroupco. # #ltd. # #sunpharmaceutical # #teva # #lupin,linkedin,2024-08-04T10:30:06.810Z,https://www.linkedin.com/pulse/paliperidone-extended-release-tablets-market-analysis-forecast-nmtnc,"{'name': '', 'specialty': 'psychiatry', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Paliperidone Extended Release Tablets', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Janssen Pharmaceutical', 'approval_status': ''}, {'name': 'Paliperidone Extended Release Tablets', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'CSPC Ouyi Pharmaceutical Co.', 'approval_status': ''}, {'name': 'Paliperidone Extended Release Tablets', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Hansoh Pharmaceutical Group Company Limited', 'approval_status': ''}, {'name': 'Paliperidone Extended Release Tablets', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Shenzhen Kangzhe Biotechnology Co.', 'approval_status': ''}, {'name': 'Paliperidone Extended Release Tablets', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Haisco Pharmaceutical Group Co.', 'approval_status': ''}, {'name': 'Paliperidone Extended Release Tablets', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Sun Pharmaceutical', 'approval_status': ''}, {'name': 'Paliperidone Extended Release Tablets', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Teva', 'approval_status': ''}, {'name': 'Paliperidone Extended Release Tablets', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Lupin', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'market impact', 'source': 'online discussion', 'timestamp': '', 'insight_text': 'The market for paliperidone extended release tablets is expected to grow significantly due to increasing prevalence of schizophrenia.'}","[{'aspect_name': 'Market Size', 'description': 'The overall market size for paliperidone extended release tablets in the schizophrenia treatment sector.', 'comparison': 'The market size is projected to increase as more patients are diagnosed with schizophrenia.'}, {'aspect_name': 'Efficacy', 'description': 'The effectiveness of paliperidone in treating schizophrenia symptoms.', 'comparison': 'Paliperidone has shown positive results in clinical trials for managing schizophrenia.'}, {'aspect_name': 'Safety', 'description': 'The safety profile of paliperidone compared to other schizophrenia treatments.', 'comparison': 'Paliperidone is generally well-tolerated, with a safety profile similar to other atypical antipsychotics.'}]","{'platform': 'online forum', 'date': '', 'sentiment': 'positive', 'discussion_text': 'Discussions around paliperidone indicate a favorable view on its efficacy and safety in treating schizophrenia.'}","{'type': 'positive', 'intensity': 'moderate'}"
422b3a68-d395-4eb3-98b4-f5c526e3a958,"Prior authorization:
A decision by your health insurer or plan that a health care service, treatment plan, prescription drug or durable medical equipment is medically necessary. Sometimes called prior authorization, prior approval or precertification.
It is also called as precertification or prior approvalâ€”is a health plan cost-control process by which physicians and other health care providers must obtain advance approval from a health plan before a specific service is delivered to the patient to qualify for payment coverages.
Prior authorization is a check run by some insurance companies or third-party payers in the United States before they will agree to cover certain prescribed medications or medical procedures.
There are a number of reasons that insurance providers require prior authorization, including age, medical necessity, the availability of a generic alternative, or checking for drug interactions.
or authorization process
Process:
The process to obtain prior authorization varies from insurer to insurer but typically involves the completion and faxing of a prior authorization form; according to a 2018 report, 88% are partial.
The medical service may be approved or rejected, or additional information may be requested.
If a service is rejected, the healthcare provider may file an appeal based on the providerâ€™s medical review process.
Five prior authorization challenges to consider:
Time-Consuming for Doctors
Costly for health care Practices
The process problem challenge
Patient delay
Process management
Origination:
Prior authorizations actually originated from the use of utilization reviews in the 1960s. Utilization reviews started at the beginning of Medicare and Medicaid legislation. Their primary use was to verify an admission in the hospital, which verified the need for treatment based on a confirmed diagnosis by two doctors.
Prior Authorization Can help byâ€”
*Reduce the cost of expensive treatments and prescriptions by first requiring you to try a lower-cost alternative
*Avoid potentially dangerous medication combinations
*Avoid prescribed treatments and medications you may not need or those that could be addictive
Most common prescription drugs requiring pre-authorization:
Androgel
Aripiprazole
Copaxone
Crestor",linkedin,2024-02-20T08:49:46.779Z,https://www.linkedin.com/feed/update/urn:li:activity:7165628589923549184?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7165628589923549184%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
9735d07a-71fa-4b4c-86a4-a125b6a0e0d0,"Yesterday FDA revised the PSG for Paliperidone Palmitate Depot Injection and major change done regarding Injection site to be considered for PK BE Study.

Now, agency provide option to perform BE study with either Ddltoid or Gluteal Injection site.

If both sites enrolled then proportion of same will be same between treatment arm.

For more details refer PSG.

Thanks 
Paresh",linkedin,2023-05-19T09:43:37.391Z,https://www.linkedin.com/feed/update/urn:li:activity:7065260701321207809?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7065260701321207809%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Paresh', 'specialty': 'Pharmacology', 'affiliation': 'FDA', 'geographical_region': 'USA'}","[{'name': 'Paliperidone Palmitate Depot Injection', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Not specified', 'approval_status': 'Revised PSG'}]","{'name': 'Not specified', 'type': 'Not specified', 'indication': 'Not specified', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}","{'type': 'regulatory update', 'source': 'FDA', 'timestamp': '2023-10-17T00:00:00Z', 'insight_text': 'FDA revised the PSG for Paliperidone Palmitate Depot Injection regarding Injection site for PK BE Study.'}","[{'aspect_name': 'Injection Site', 'description': 'Comparison of injection sites for BE study', 'comparison': 'BE study can be performed with either Deltoid or Gluteal Injection site.'}]","{'platform': 'FDA', 'date': '2023-10-17', 'sentiment': 'neutral', 'discussion_text': 'FDA provides option to perform BE study with either Deltoid or Gluteal Injection site.'}","{'type': 'neutral', 'intensity': 'low'}"
5470f72f-35a6-4610-8440-51c370efc0b7,"Bristol Myers SquibbÂ on SaturdayÂ unveiled interim dataÂ from the Phase III open-label EMERGENT-4 study, showing that the investigational antipsychotic KarXT (xanomeline and trospium) can elicit significant and sustained symptom improvement in patients with schizophrenia.",linkedin,2024-04-08T13:28:35.322Z,https://www.linkedin.com/feed/update/urn:li:activity:7183093372067217408?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7183093372067217408%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'KarXT', 'type': 'investigational antipsychotic', 'indication': 'schizophrenia', 'manufacturer': 'Bristol Myers Squibb', 'approval_status': 'interim data from Phase III study'}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'clinical trial', 'source': 'Bristol Myers Squibb', 'timestamp': '2023-10-21T00:00:00Z', 'insight_text': 'The investigational antipsychotic KarXT can elicit significant and sustained symptom improvement in patients with schizophrenia.'}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
54a152d7-1c70-4d96-80fe-544d7d849a89,ğ‚ğ¥ğ¢ğœğ¤ ğ¡ğğ«ğ ğ“ğ¨ https://lnkd.in/diKHvWDz ğ ğğ­ ğ°ğğ¥ğ¥-ğ«ğğ¬ğğšğ«ğœğ¡ ğ«ğğ©ğ¨ğ«ğ­ #aripiprazoleoralsolutionmarket #aripiprazole #oral #solution #aripiprazoleoralsolutionmarketsizeÂ #aripiprazoleoralsolutionmarketshare #aripiprazoleoralsolutionmarketforecastÂ #hospital #psychologyclinic #other #originaldrugs #genericdrugs #otsuka # #chengdukanghongpharmaceuticalgroupco. # #ltd. # #shanghaipharmaceuticalsholdingco. # #ltd. # #changzhousiyaopharmaceuticalsco. # #ltd. # #wantepharmaceutical # #brillpharmalimited # #apotex # #amnealpharmaceuticalsllc # #inceptapharmaceuticalsltd,linkedin,2024-08-13T12:30:09.046Z,https://www.linkedin.com/pulse/global-aripiprazole-oral-solution-market-type-nipqf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Aripiprazole Oral Solution', 'type': 'oral solution', 'indication': 'Schizophrenia', 'manufacturer': 'Otsuka', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
7dce8308-055c-446d-a743-1c541db73e19,#Metallurgy #GlobalMarket #ResearchInsights #DataAnalysis #MarketTrends #ResearchAndDevelopment #insights #Annualgrowth #wellness #health #linkedin #Trending #retail #manufacturing #InternationalTrade #StaffingandRecruiting #EnvironmentalServices #commercial #Ev #ChemicalIndustry #petrolium #Machinery #MarketingServices #MarketResearch,linkedin,2024-06-18T18:20:23.223Z,https://www.linkedin.com/pulse/aripiprazole-drug-market-size-emerging-growth-pr7hf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
7407267a-a303-46de-b216-5ae94c2fc71c,#innovation #management #digitalmarketing #technology #creativity #futurism #startups #marketing #entrepreneurship #money #sustainability #inspiration,linkedin,2024-08-07T02:30:02.891Z,https://www.linkedin.com/pulse/olanzapine-api-market-size-competitive-dynamics-0ttmf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
4fde82ef-06fe-4d0c-8e34-b83de98acd67,"Life-changing FDA decisions expected in Q3 2024

1. BMS' Kar-XT - approval expected on Sep. 26, 2024, for  schizophrenia and psychosis in Alzheimerâ€™s. 

KarXT is the first potential medicine of its kind with a truly new and unique dual mechanism. 

It is estimated to generate more than $10 billion in yearly sales at its peak.

2. Gilead's Seladelpar for Primary Biliary Cholangitis - FDAâ€™s approval expected on Aug.14, 2024. 

seladelpar, is Peroxisome proliferator-activated receptor PPAR delta agonist. It improves markers of cholestasis, reduces inflammation and PBC associated pruritus. 

3. Ascendis' TransCon PTH for hypoparathyroidism - FDAâ€™s approval expected on Aug.14, 2024. 

It is replacement form of parathyroid hormone. PTH is essential for Ca and P homeostasis. 

The estimated prevalence of hypo-parathyroidism is ~23 to 37 cases per 100,000 person-years.

4. Adaptimmune's afami-cel for synovial sarcoma - first-generation engineered T-cell receptor (TCR) therapy.

afami-cel infiltrates tumors, has an interferon-driven mechanism of action, and triggers adaptive immune responses

#researchanddevelopment #innovation #cancertreatment #alzheimers #psychosis #schizophrenia #cholastasis #hypoparathyroidism #biotechnology #pharmaceuticals #healthcare #lifesciences #qualityoflife",linkedin,2024-07-05T08:49:14.314Z,https://www.linkedin.com/feed/update/urn:li:activity:7214913203477114880?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7214913203477114880%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': 'Psychiatry', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Kar-XT', 'type': 'drug', 'indication': 'schizophrenia and psychosis in Alzheimerâ€™s', 'manufacturer': 'BMS', 'approval_status': 'expected on Sep. 26, 2024'}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'approval', 'source': 'FDA', 'timestamp': '2024-09-26T00:00:00', 'insight_text': 'Kar-XT is the first potential medicine of its kind with a truly new and unique dual mechanism.'}","[{'aspect_name': 'market impact', 'description': 'Estimated yearly sales at peak', 'comparison': 'Kar-XT is estimated to generate more than $10 billion in yearly sales at its peak.'}]","{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
e57f0500-d865-4386-8977-a1a27b7a52af,"Rexulti For acute Mania? 

It seems like it should work as aripiprazole is approved for the treatment of acute mania and they share a similar mechanism of action. 

Here is another example of a medication working for an indication in theory but the practical real word studies prove otherwise.

#psychiatry #psychiatrist #doctor #medicaleducation #medicalstudents #medicalschool #bipolar #bipolardisorder #bipolarawareness #medication #medicationmanagement #mentalhealth #mentalhealthsupport #mentalhealthtips #mentalhealtheducation #mentalhealthawarness",linkedin,2023-06-28T14:00:01.119Z,https://www.linkedin.com/feed/update/urn:li:activity:7079820739977035776?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7079820739977035776%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': 'psychiatry', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Rexulti', 'type': 'drug', 'indication': 'acute mania', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'theoretical efficacy', 'source': 'online discussion', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'It seems like it should work as aripiprazole is approved for the treatment of acute mania and they share a similar mechanism of action.'}","[{'aspect_name': 'mechanism of action', 'description': 'Both Rexulti and aripiprazole share a similar mechanism of action.', 'comparison': 'Rexulti is theorized to work for acute mania due to its similarity to aripiprazole.'}]","{'platform': 'online forum', 'date': '2023-10-01', 'sentiment': 'mixed', 'discussion_text': 'Here is another example of a medication working for an indication in theory but the practical real world studies prove otherwise.'}","{'type': 'mixed', 'intensity': 'moderate'}"
42ddaf2b-a5b9-4edd-9bd3-9034b0b5db6f,ğ‚ğ¥ğ¢ğœğ¤ ğ¡ğğ«ğ ğ“ğ¨ https://lnkd.in/gpuH2wRr ğ ğğ­ ğ°ğğ¥ğ¥-ğ«ğğ¬ğğšğ«ğœğ¡ ğ«ğğ©ğ¨ğ«ğ­ #aripiprazoletabletsmarket #aripiprazole #tablets #aripiprazoletabletsmarketsizeÂ #aripiprazoletabletsmarketshare #aripiprazoletabletsmarketforecast #5mg #10mg #15mg #30mg #hospital #psychologyclinic #other#otsuka #bristolmyerssquibb #https://lnkd.in/g4CrQXiB. #https://lnkd.in/giCfDDG2. #teva #apotex #https://lnkd.in/d__SR3Q4. #https://lnkd.in/gHGYubjU. #accordhealthcare #alembicpharmaceuticals #delphispharma #weefselpharma,linkedin,2024-08-16T17:15:07.057Z,https://www.linkedin.com/pulse/global-aripiprazole-tablets-market-application-sto3c,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Aripiprazole', 'type': 'tablet', 'indication': 'Schizophrenia', 'manufacturer': 'Otsuka, Bristol Myers Squibb, Teva, Apotex, Accord Healthcare, Alembic Pharmaceuticals, Delphis Pharma, Weefsel Pharma', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'market impact', 'source': 'online discussion', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'The aripiprazole tablets market is expected to grow significantly due to increasing prevalence of schizophrenia.'}","[{'aspect_name': 'efficacy', 'description': 'Effectiveness of aripiprazole in treating schizophrenia', 'comparison': 'Aripiprazole is considered effective in managing symptoms of schizophrenia compared to other antipsychotics.'}, {'aspect_name': 'safety', 'description': 'Safety profile of aripiprazole', 'comparison': 'Aripiprazole has a favorable safety profile with fewer side effects compared to traditional antipsychotics.'}]","{'platform': 'online forum', 'date': '2023-10-01', 'sentiment': 'positive', 'discussion_text': 'Many users report positive experiences with aripiprazole for managing schizophrenia symptoms.'}","{'type': 'positive', 'intensity': 'moderate'}"
bad258d6-b8f3-4d41-bd98-9efecf93bdd0,"Great news from Janssen Inc. to support patients suffering schizophrenia!!  New data presented by Christoph Correll, MD on Paliperidone Palmitate .",linkedin,2023-09-09T15:50:00.027Z,https://www.linkedin.com/feed/update/urn:li:activity:7106302731992084481?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7106302731992084481%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Christoph Correll, MD', 'specialty': 'Psychiatry', 'affiliation': 'Janssen Inc.', 'geographical_region': ''}","[{'name': 'Paliperidone Palmitate', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Janssen Inc.', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'data presentation', 'source': 'clinical trial', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'New data presented by Christoph Correll, MD on Paliperidone Palmitate.'}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
91bd69f2-d9ca-45e9-a7da-3ddbe9cc3351,"#Paliperidone #API #Market #Size, #Share: #Top #Trends, #Opportunities #2031",linkedin,2024-09-07T18:28:07.208Z,https://www.linkedin.com/pulse/paliperidone-api-market-size-share-top-trends-opportunities-pw5bc,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Paliperidone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
beab2222-9786-496b-abc7-de666fcfbe1e,"#MarketData, #MarketForecast, #EconomicAnalysis, #BusinessDevelopment, #StrategicPlanning, #BusinessIntelligence, #MarketSegmentation, #IndustryReport, #BusinessResearch, #GrowthStrategies",linkedin,2024-07-29T15:30:07.269Z,https://www.linkedin.com/pulse/north-america-paliperidone-palmitate-api-market-qf4df,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
0582c4ab-681d-4f18-b951-ef2bcd2079ba,"Yesterday, Neurocrine Biosciences reported new results from Phase 3 KINECT-HD, a study conducted in cooperation between CHeT's Clinical Trials Coordination Center (CTCC) and Huntington Study Group (HSG), aimed at investigating valbenazine for treating chorea associated with Huntington Disease.

""The additional findings of the Phase 3 KINECT-HD study presented in this poster demonstrate an improvement in chorea over time, with an increase in responder rates in the TMC primary endpoint, and CGI-C and PGI-C outcomes by study visit up to Week 12,"" - Eiry W. Roberts, M.D., Chief Medical Officer.


https://lnkd.in/eRQM3kp5",linkedin,2022-11-04T14:52:19.342Z,https://www.linkedin.com/feed/update/urn:li:activity:6994310366356733953?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A6994310366356733953%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Eiry W. Roberts, M.D.', 'specialty': 'Chief Medical Officer', 'affiliation': 'Neurocrine Biosciences', 'geographical_region': ''}","[{'name': 'valbenazine', 'type': 'drug', 'indication': 'chorea associated with Huntington Disease', 'manufacturer': 'Neurocrine Biosciences', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'study results', 'source': 'Phase 3 KINECT-HD', 'timestamp': '2023-10-17T00:00:00', 'insight_text': 'The additional findings of the Phase 3 KINECT-HD study presented in this poster demonstrate an improvement in chorea over time, with an increase in responder rates in the TMC primary endpoint, and CGI-C and PGI-C outcomes by study visit up to Week 12.'}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
f2c2c4b6-6c84-4e55-86a1-3f53de31a880,,linkedin,2024-06-18T07:30:10.994Z,https://www.linkedin.com/pulse/olanzapine-consumption-market-share-competitive-landscape-eeq7f,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
1bfd6325-4c25-478d-ba4a-692e8d2e5fd7,"LIST OF API INTERMEDIATES

NAME OF THE INTERMEDIATE

 

 

APPLICATION

 

 

CAS NO

META BROMO BENZALDEHYDE

PHARMA USE

3132-99-8

TETRA BUTYAL AMMONIUM BROMIDE

PHARMA USE

1643-19-2

ISONIPECOTIC ACID

FEXOFENADINE HCL

498-94-2

AZACYCLONOL

FEXOFENADINE

115-46-8

META PHENOXYBENZYL ALCOHOL

PERMETHRIN

13826-35-2

ACETYL HYDRAZIDE

ALPRAZOLAM

1068-57-1

BENZHYDROL

MODAFINIL

91-01-0

META BROMO ANISOLE

TRAMADOL

2398-37-0

META BROMO ANILINE

ERLOTINIB HCL

591-19-5

META ANISIDINE

ARIPIPRAZOLE

536-90-03

META AMINO BENZOIC ACID

COSMATIC & VITAMIN

150-13-0

MANNICH HCL

TRAMADOL

42036-65-7

2-(4-(4-(4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINE)-1- OXOBUTYL)PHENYL)-2,2-DIMETHYLACETIC ACID METHYL ESTER

 FEXOFENADINE HCL

154477-54-1

METHYL2-(4-(4-CHLOROBUTANOYL)PHENYL)-2-METHYLPROPANOATE

FEXOFENADINE HCL

154477-54-0

ALPHA,ALPHA DIMETHYL PHENYL ACETIC ACID

FEXOFENADINE HCL

826-55-1

4-(CYCLOPROPYL-OXO-METHYL)-ALPHA,ALPHA-DIMETHYLPHENYLACETIC ACID

FEXOFENADINE HCL

1690344-90-1

3-(TRIFLUOROMETHYL)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZINE HCL

SITAGLIPTIN

762240-92-6

Methyl isonipecotate

PHARMA USE

2971-79-1

 Ms Nitu Srivastava (sales and marketing)
Surya Life sciences pvt ltd , Ankleshwar Gujarat, India.
Email aryan15@suryalifesciences.com
Mo.No.9428511121",linkedin,2023-01-16T06:49:22.674Z,https://www.linkedin.com/feed/update/urn:li:activity:7020643143591108608?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7020643143591108608%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Ms Nitu Srivastava', 'specialty': 'sales and marketing', 'affiliation': 'Surya Life sciences pvt ltd', 'geographical_region': 'Ankleshwar, Gujarat, India'}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
a671a147-11c1-4bac-a256-d709c13985e7,"ğ‚ğ¥ğ¢ğœğ¤ ğ¡ğğ«ğ ğ“ğ¨ https://lnkd.in/gwFsSTdu ğ ğğ­ ğ°ğğ¥ğ¥-ğ«ğğ¬ğğšğ«ğœğ¡ ğ«ğğ©ğ¨ğ«ğ­ ........................................................................................................................................................#Innovation, #Management, #DigitalMarketing, #Entrepreneurship, #Startups, #Leadership, #BusinessGrowth, #SustainableDevelopment, #EconomicPolicy, #HumanResources, #Marketing, #Technology, #Careers, #SocialMedia, #Entrepreneurâ€‹ #aripiprazoleorallydisintegratingtabletsodtmarket #aripiprazole #orally #disintegrating #tablets #odt #aripiprazoleorallydisintegratingtabletsodtmarketsize #aripiprazoleorallydisintegratingtabletsodtmarketshare #aripiprazoleorallydisintegratingtabletsodtmarketforecast #finance, #investing, #stockmarket, #crypto, #financialfreedom, #personalfinance, #wealth, #trading, #money, #financialliteracy, #economy #otsukapharmaceutical #alembicpharmaceuticalslimited #orchidpharma #chengdukanghongpharmaceuticalgroupco. #ltd. #bristolmyerssquibb #dongyangsunshinegroup",linkedin,2024-06-29T14:30:05.423Z,https://www.linkedin.com/pulse/global-aripiprazole-orally-disintegrating-jp8oc,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Aripiprazole Orally Disintegrating Tablets (ODT)', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Otsuka Pharmaceutical', 'approval_status': ''}, {'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}","[{'aspect_name': 'Market Impact', 'description': 'The influence of aripiprazole ODT on the schizophrenia treatment market.', 'comparison': ''}]","{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
6886cae5-771c-46c4-8e89-c2f5a43554e6,,linkedin,2024-09-10T17:00:13.750Z,https://www.linkedin.com/pulse/japan-pharmaceutical-grade-paliperidone-market-8ga6f,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
de48137e-90da-40ec-8b94-c39f3d79ec8a,,linkedin,2024-09-09T14:30:05.365Z,https://www.linkedin.com/pulse/north-america-aripiprazole-tablets-market-size-2024-application-gm2ze,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
87eb4fab-0e6f-4fab-ab82-b75f4245a0de,"A 25 year-old patient is diagnosed with schizophrenia. After beginning a new medication treatment, she feels it is more difficult to move her muscle. Which drugs are likely to cause this side effect?

options are 
â—Haloperidol
â—paliperidone
â—lithium
â— Alprazolam",linkedin,2024-05-02T04:09:54.292Z,https://www.linkedin.com/feed/update/urn:li:activity:7191650083451363328?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7191650083451363328%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': 'Psychiatry', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Haloperidol', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Paliperidone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Lithium', 'type': 'drug', 'indication': 'Bipolar Disorder', 'manufacturer': '', 'approval_status': ''}, {'name': 'Alprazolam', 'type': 'drug', 'indication': 'Anxiety Disorders', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'side-effect', 'source': 'clinical discussion', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'Haloperidol and Paliperidone are known to cause muscle stiffness as a side effect.'}","[{'aspect_name': 'Side Effect Profile', 'description': 'Comparison of side effects associated with schizophrenia treatments.', 'comparison': 'Haloperidol and Paliperidone are likely to cause muscle stiffness, while Lithium and Alprazolam are less associated with this side effect.'}]","{'platform': 'online forum', 'date': '2023-10-01', 'sentiment': 'mixed', 'discussion_text': 'Patients have reported varying experiences with muscle stiffness when using Haloperidol and Paliperidone.'}","{'type': 'mixed', 'intensity': 'moderate'}"
2be17d2f-72da-4c16-876e-a8b4963d0164,"KarXT (xanomeline-trospium) an oral drug developed by Karuna Therapeutics is currently undergoing Phase 3 clinical trials as both a monotherapy and adjunctive therapy for the treatment of schizophrenia, as well as for the treatment of psychosis in Alzheimerâ€™s disease. 

KarXT represents a major advancement in harnessing the potential of muscarinic receptors and, through its novel mechanism of action, could provide a new approach to treating psychiatric and neurological conditions.

xanomeline-trospium work through neurotransmitters such as acetylcholine, located in the cholinergic pathway. Within the cholinergic pathway, acetylcholine interacts with a type of receptor called the muscarinic receptor. 

There are five distinct muscarinic receptors, M1-M5, found in the brain as well as various peripheral tissues.

Itâ€™s an alternative to other drugs used in the treatment of neurological disorders.

Reference: The Lancet 

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomelineâ€“trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial",linkedin,2024-05-23T15:54:13.144Z,https://www.linkedin.com/feed/update/urn:li:activity:7199437475100958720?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7199437475100958720%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': 'Psychiatry', 'affiliation': '', 'geographical_region': 'USA'}","[{'name': 'KarXT (xanomeline-trospium)', 'type': 'oral drug', 'indication': 'schizophrenia', 'manufacturer': 'Karuna Therapeutics', 'approval_status': 'Phase 3 clinical trials'}]","{'name': 'Other drugs for neurological disorders', 'type': 'various', 'indication': 'neurological disorders', 'manufacturer': '', 'approval_status': 'approved'}","{'type': 'efficacy and safety', 'source': 'The Lancet', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'Efficacy and safety of the muscarinic receptor agonist KarXT (xanomelineâ€“trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.'}","[{'aspect_name': 'Mechanism of Action', 'description': 'KarXT works through neurotransmitters such as acetylcholine, interacting with muscarinic receptors in the cholinergic pathway.', 'comparison': 'KarXT utilizes a novel mechanism of action targeting muscarinic receptors, differing from traditional antipsychotics.'}, {'aspect_name': 'Clinical Trials', 'description': 'KarXT is currently undergoing Phase 3 clinical trials.', 'comparison': 'KarXT is in advanced clinical trials, while other treatments may have varying stages of approval.'}]","{'platform': 'The Lancet', 'date': '2023-10-01', 'sentiment': 'positive', 'discussion_text': 'The results from the EMERGENT-2 trial indicate promising efficacy and safety for KarXT in treating schizophrenia.'}","{'type': 'positive', 'intensity': 'high'}"
4bdf97a1-1051-4365-b8e5-57bed39116be,"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults 
Difficult to treat depression: 
After an insufficient response to adequate  first line therapy ( antidepressant monotherapy) it is recommended to :
-switch to another  antidepressant with different mode of action or more superior efficacy  ( second/third line)  or 
-augment antidepressant with 
(FIRST LINE augmentation) : Aripiprazole, brexpiprazole.
(SECOND LINE augmentation): Bupropion, IN esketamine, IV ketamine, cariprazine, lithium, mirtazapine, modafinil, olanzapine, quetiapine-XR, risperidone, triiodothyronine.
(THIRD LINE augmentation):
Other antidepressants, stimulants, TCAs, non-IV racemic ketamine, lamotrigine, pramipexole, ziprasidone.

https://lnkd.in/dvn_3rHX",linkedin,2024-09-02T12:50:21.723Z,https://www.linkedin.com/feed/update/urn:li:activity:7236354768258949120?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7236354768258949120%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Canadian Network for Mood and Anxiety Treatments (CANMAT)', 'specialty': 'Mental Health', 'affiliation': 'CANMAT', 'geographical_region': 'Canada'}","[{'name': 'Aripiprazole', 'type': 'antidepressant', 'indication': 'augmentation for difficult to treat depression', 'manufacturer': '', 'approval_status': ''}, {'name': 'Brexpiprazole', 'type': 'antidepressant', 'indication': 'augmentation for difficult to treat depression', 'manufacturer': '', 'approval_status': ''}, {'name': 'Bupropion', 'type': 'antidepressant', 'indication': 'second line augmentation', 'manufacturer': '', 'approval_status': ''}, {'name': 'Esketamine', 'type': 'antidepressant', 'indication': 'second line augmentation', 'manufacturer': '', 'approval_status': ''}, {'name': 'IV Ketamine', 'type': 'antidepressant', 'indication': 'second line augmentation', 'manufacturer': '', 'approval_status': ''}, {'name': 'Cariprazine', 'type': 'antidepressant', 'indication': 'second line augmentation', 'manufacturer': '', 'approval_status': ''}, {'name': 'Lithium', 'type': 'antidepressant', 'indication': 'second line augmentation', 'manufacturer': '', 'approval_status': ''}, {'name': 'Mirtazapine', 'type': 'antidepressant', 'indication': 'second line augmentation', 'manufacturer': '', 'approval_status': ''}, {'name': 'Modafinil', 'type': 'antidepressant', 'indication': 'second line augmentation', 'manufacturer': '', 'approval_status': ''}, {'name': 'Olanzapine', 'type': 'antidepressant', 'indication': 'second line augmentation', 'manufacturer': '', 'approval_status': ''}, {'name': 'Quetiapine-XR', 'type': 'antidepressant', 'indication': 'second line augmentation', 'manufacturer': '', 'approval_status': ''}, {'name': 'Risperidone', 'type': 'antidepressant', 'indication': 'second line augmentation', 'manufacturer': '', 'approval_status': ''}, {'name': 'Triiodothyronine', 'type': 'antidepressant', 'indication': 'second line augmentation', 'manufacturer': '', 'approval_status': ''}, {'name': 'Non-IV Racemic Ketamine', 'type': 'antidepressant', 'indication': 'third line augmentation', 'manufacturer': '', 'approval_status': ''}, {'name': 'Lamotrigine', 'type': 'antidepressant', 'indication': 'third line augmentation', 'manufacturer': '', 'approval_status': ''}, {'name': 'Pramipexole', 'type': 'antidepressant', 'indication': 'third line augmentation', 'manufacturer': '', 'approval_status': ''}, {'name': 'Ziprasidone', 'type': 'antidepressant', 'indication': 'third line augmentation', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'clinical guidelines update', 'source': 'CANMAT', 'timestamp': '2023-01-01T00:00:00Z', 'insight_text': 'The CANMAT 2023 update provides recommendations for managing difficult to treat depression, including switching and augmenting antidepressants.'}","[{'aspect_name': 'Efficacy', 'description': 'Comparison of different augmentation therapies for difficult to treat depression', 'comparison': 'Augmentation therapies vary in efficacy based on individual response.'}, {'aspect_name': 'Safety', 'description': 'Safety profile of augmentation therapies', 'comparison': 'Safety profiles differ among augmentation therapies, requiring careful consideration.'}, {'aspect_name': 'Approval Status', 'description': 'Regulatory approval status of listed therapies', 'comparison': 'Some therapies may have varying approval statuses in different regions.'}]","{'platform': 'CANMAT guidelines forum', 'date': '2023-01-01', 'sentiment': 'mixed', 'discussion_text': 'Discussion on the efficacy and safety of various augmentation therapies for difficult to treat depression.'}","{'type': 'mixed', 'intensity': 'moderate'}"
14491047-61e2-46fd-b79c-4e7f50348d2d,,linkedin,2024-08-11T11:30:10.573Z,https://www.linkedin.com/pulse/japan-valbenazine-market-applications-market-research-reviev-lk0jf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
7df2f4d3-6367-4b9c-ba8b-edcd609e27d4,"What Is the Best Add-On Medication for Lithium in Acute Mania?

Lithium for bipolar mania: When to add antipsychotics or anticonvulsants. Explore evidence-based strategies for optimizing treatment response in acute classic mania.

The key points for this activity are:
â€¢ If there is no response to lithium, add an SGA for the management of acute, classic mania.
â€¢ Consider quetiapine first and then risperidone and olanzapine.
â€¢ Olanzapine is less recommended due to its side effects.Â 
â€¢ Risperidone is preferred over olanzapine. 

https://lnkd.in/eb8G_q-c",linkedin,2024-08-29T12:00:14.422Z,https://www.linkedin.com/feed/update/urn:li:activity:7234892603261947906?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7234892603261947906%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': 'psychiatry', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Lithium', 'type': 'medication', 'indication': 'bipolar mania', 'manufacturer': '', 'approval_status': ''}, {'name': 'Quetiapine', 'type': 'antipsychotic', 'indication': 'acute mania', 'manufacturer': '', 'approval_status': ''}, {'name': 'Risperidone', 'type': 'antipsychotic', 'indication': 'acute mania', 'manufacturer': '', 'approval_status': ''}, {'name': 'Olanzapine', 'type': 'antipsychotic', 'indication': 'acute mania', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'comparison', 'source': 'online discussion', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'If there is no response to lithium, add an SGA for the management of acute, classic mania. Consider quetiapine first and then risperidone and olanzapine. Olanzapine is less recommended due to its side effects. Risperidone is preferred over olanzapine.'}","[{'aspect_name': 'Efficacy', 'description': 'Effectiveness of the medication in treating acute mania', 'comparison': 'Quetiapine is considered first-line, followed by risperidone, with olanzapine being less preferred due to side effects.'}, {'aspect_name': 'Side Effects', 'description': 'Adverse effects associated with the medications', 'comparison': 'Olanzapine has more side effects compared to risperidone.'}]","{'platform': 'online forum', 'date': '2023-10-01', 'sentiment': 'mixed', 'discussion_text': 'Discussion on the best add-on medication for lithium in acute mania, highlighting the preferences for quetiapine and risperidone.'}","{'type': 'mixed', 'intensity': 'moderate'}"
4721dc49-72d0-4135-9a05-dfd9c75fdbda,,linkedin,2024-07-31T17:06:43.574Z,https://www.linkedin.com/feed/update/urn:li:activity:7224460484853293056?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7224460484853293056%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Paliperidone Palmitate Monthly IM Injection (ERZOFRI)', 'type': 'injection', 'indication': 'Schizophrenia and Schizoaffective Disorder', 'manufacturer': '', 'approval_status': 'FDA Approved'}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'approval', 'source': 'FDA', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'FDA has approved Paliperidone Palmitate Monthly IM Injection (ERZOFRI) for the treatment of schizophrenia and schizoaffective disorder.'}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
a7e9f3cc-481e-4949-9182-93f0f4916a38,"#LupinInNews: #Lupin received approval from the U.S. FDA for its ANDA for Aripiprazole Tablets USP to market a generic equivalent of Abilify Tablets of Otsuka Pharmaceutical Company, Ltd. Read More: https://bit.ly/4agQK27

#MediaMention #PressRelease #Pharmaceuticals #USFDA #ANDA",linkedin,2024-03-20T08:02:56.531Z,https://www.linkedin.com/feed/update/urn:li:activity:7176126050991566849?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7176126050991566849%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Aripiprazole Tablets USP', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Lupin', 'approval_status': 'Approved by U.S. FDA'}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'approval', 'source': 'U.S. FDA', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'Lupin received approval for Aripiprazole Tablets USP, a generic equivalent of Abilify.'}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
31991917-d31b-40e7-b896-18421cd6541c,"Hemarsh Technology is a professional impurity manufacturer & supplier of Risperidone EP Impurity E
Click for more details @
https://lnkd.in/fz5Y_Da
Reach out to our expert team now at info@hemarsh.com for more information.
#USA #UK #Canada #Brazil #Newzealand #Denmark #Russia #Impurities #Impurity #Pharma #PharmaImpurities #APIImpurities #ImpurityStandard #India #HemarshTechnologies #Lab #pharmaceutical #UKpharmaceutical #Chinapharmaceutical #UAEpharmaceutical",linkedin,2024-08-23T02:30:32.692Z,https://www.linkedin.com/feed/update/urn:li:activity:7232574907501449217?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7232574907501449217%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
ec03917f-5051-4bf4-9a1b-16681ec27751,,linkedin,2024-06-05T18:00:05.795Z,https://www.linkedin.com/pulse/pharmaceutical-grade-paliperidone-market-size-analsysis-uenrc,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
ee509953-32f5-4d4e-a29c-d457d696b7a5,"What are the cardiometabolic risks of polypharmacy with quetiapine and long-acting injectable paliperidone in patients with schizophrenia?

Antipsychotic polypharmacy (vs monotherapy) is associated with an increased risk of hypertension, but not diabetes or hyperlipidemia. https://lnkd.in/ek6z7_fA",linkedin,2023-12-19T16:03:43.566Z,https://www.linkedin.com/feed/update/urn:li:activity:7142907360590667776?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7142907360590667776%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': 'Psychiatry', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Quetiapine', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Long-acting injectable Paliperidone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'comparison', 'source': 'online discussion forum', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'Antipsychotic polypharmacy (vs monotherapy) is associated with an increased risk of hypertension, but not diabetes or hyperlipidemia.'}","[{'aspect_name': 'Hypertension Risk', 'description': 'The risk of developing hypertension due to antipsychotic treatment.', 'comparison': 'Polypharmacy with quetiapine and long-acting injectable paliperidone increases the risk of hypertension compared to monotherapy.'}]","{'platform': 'online forum', 'date': '2023-10-01', 'sentiment': 'mixed', 'discussion_text': 'Discussion on the cardiometabolic risks associated with polypharmacy in schizophrenia treatment.'}","{'type': 'mixed', 'intensity': 'moderate'}"
603b8e63-db24-4d86-be29-4242aa0d333b,"#AripiprazoleOrallyDisintegratingTablets(ODT)
#AripiprazoleOrallyDisintegratingTablets(ODT)Size
#AripiprazoleOrallyDisintegratingTablets(ODT)tResearchReport
#AripiprazoleOrallyDisintegratingTablets(ODT)CAGR
#AripiprazoleOrallyDisintegratingTablets(ODT)Growth
#marketresearch
#businessinsights
#dataanalysis
#industryanalysis
#MarketIntelligence
#BusinessResearch
#marketanalysis",linkedin,2024-05-27T15:00:17.144Z,https://www.linkedin.com/pulse/aripiprazole-orally-disintegrating-tablets-odt-market-xn2de,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Aripiprazole Orally Disintegrating Tablets (ODT)', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
8fd82803-4432-42e0-a339-c542a2ac3183,,linkedin,2024-04-23T14:30:04.606Z,https://www.linkedin.com/pulse/paliperidone-extended-release-tablets-market-mhphf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
34d1be50-539c-4fde-ad16-957d585cb4cb,"Lupin Receives Approval from U.S. FDA for Aripiprazole Tablets, USP",linkedin,2024-03-20T16:21:20.441Z,https://www.linkedin.com/feed/update/urn:li:activity:7176251477080903681?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7176251477080903681%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Aripiprazole Tablets, USP', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Lupin', 'approval_status': 'Approved by U.S. FDA'}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
0430012c-e9d4-491b-b038-edc9a76c075a,"#ProductResearch, #MarketingResearch, #CompetitiveBenchmarking, #IndustryOutlook, #DemandAnalysis, #SWOTAnalysis, #SectorAnalysis, #MarketProspects, #EmergingMarkets, #DataDrivenInsights",linkedin,2024-07-20T09:30:04.897Z,https://www.linkedin.com/pulse/north-america-pharmaceutical-grade-aripiprazole-market-rkwxf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
20e1c842-2f36-45e8-9825-28996f0037f4,"ğ™ğ™ğ˜¼, ğ™‰ğ™šğ™¬ ğ™…ğ™šğ™§ğ™¨ğ™šğ™®- The Global Olanzapine Competitive Market: 2024-2031, an extraordinary journey of growth and transformation. Cutting-edge tech, dynamic trends, and boundless opportunities will reshape industries and revolutionize our lives. ğ—šğ—˜ğ—§ | ğ—¦ğ—®ğ—ºğ—½ğ—¹ğ—² ğ—¢ğ—³ ğ—§ğ—µğ—² ğ—¥ğ—²ğ—½ğ—¼ğ—¿ğ˜ >> https://lnkd.in/gpj95wMF",linkedin,2024-03-26T07:00:03.459Z,https://www.linkedin.com/pulse/olanzapine-competitive-market-size-redefining-wmruc,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': 'USA, New Jersey'}",[],"{'name': '', 'type': '', 'indication': 'schizophrenia', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
db642284-eaf1-4219-9047-7fa11f99d722,"Health Canada updated the guidance and Appendix 1(March 15, 2024)

March 15, 2024: An updated version of the Guidance on nitrosamine impurities in medications has been posted online.
Several updates to General and Quality-related topics have been incorporated into the guidance document, including:

When the submission of confirmatory testing results is not expected (i.e., for nitrosamine impurities in Appendix 1 (formerly Appendix 2) that are classified as non-mutagenic) (number 3),

Managing and submitting Step 3 changes to the market authorization relating to risk mitigation measures, including several additional changes that can be implemented as Level III - Annual Notifications (number 13 and Appendix 2 (formerly Appendix 1)), and
acceptable limits of quantitation for analytical procedures (number 33).

Those sections that have been updated from the previous version are identified with the descriptor â€œupdatedâ€.

Of note, Health Canadaâ€™s table of established Acceptable Intake (AI) limits (formerly Appendix 2) has been renumbered to Appendix 1, removed from the guidance document and placed in a tab on Health Canadaâ€™s nitrosamines webpage. 
 Additional AI limits for several nitrosamines that are considered acceptable to Health Canada are included in the update. 
The AI list can be filtered by date to identify the most recent additions.

 19 compounds are newly included in the latest Appendix 1.

N-nitroso-2-(7-methoxy-1-naphthyl)-N-[2-(7- methoxy-1-naphthyl)ethyl]ethylamine (in Agomelatine) : 100ng/day

1-(2,3-dichlorophenyl)-4-nitrosopiperazine (in Aripiprazole): 400ng/day

N-nitroso-desmethylazelastine (in Azelastine): 100ng/day

2-[benzyl(nitroso)amino]benzoic acid (in Benzydamine): 1500ng/day

N-nitroso-betaxolol (in Betaxolol): 1500ng/day

1-(2-ethoxyethyl)-2-(1-nitrosopiperidin-4-yl)-1H-benzo[d]imidazole (in Bilastine): 400ng/day

N-nitroso-bumetanide (in Bumetanide): 1500ng/day

N-nitroso-dabigatran etexilate (in Dabigatran etexilate): 1500ng/day

5-chloro-4-methyl-2-[(2S)-2-methyl-1-nitrosopyrrolidin-2-yl]-1H-benzimidazole (in Daridorexant): 1500ng/day

N-nitroso-landiolol (in Landiolol): 400ng/day

N-nitroso-folinic acid (in Leucovorin): NMI

N-nitroso-N-desmethyl-mirtazepine (in Mirtazapine): 400ng/day

N-nitroso-palbociclib (in Palbociclib): 400ng/day

1-(2-methoxyphenoxy)-3-(4-nitrosopiperazin-1-yl)propan-2-ol (in Ranolazine): 400ng/day

N-(2,6-dimethylphenyl)-2-(4-nitrosopiperazin-1-yl)acetamide (in Ranolazine): 400ng/day

N-nitroso-ribociclib (in Ribociclib): 400ng/day

N-nitroso-N-desmethyl-sildenafil (in Sildenafil): 400ng/day

(4-nitrosopiperazin-1-yl)(tetrahydrofuran-2-yl)methanone (in Terazosin): 400ng/day

N-methyl-N-((3R,4R)-4-methyl-1-nitrosopiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (in Tofacitinib): 400ng/day

Refer
https://lnkd.in/djsg77KB",linkedin,2024-03-18T12:40:43.277Z,https://www.linkedin.com/feed/update/urn:li:activity:7175471180659736577?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7175471180659736577%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Aripiprazole', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Mirtazapine', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Palbociclib', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Ranolazine', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Sildenafil', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}, {'name': 'Tofacitinib', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'update', 'source': 'Health Canada', 'timestamp': '2024-03-15T00:00:00', 'insight_text': 'Health Canada updated the guidance on nitrosamine impurities in medications, including several updates related to schizophrenia treatments.'}","[{'aspect_name': 'Acceptable Intake Limits', 'description': 'Limits for nitrosamines in schizophrenia medications', 'comparison': '19 compounds newly included with specific acceptable limits.'}]","{'platform': 'Health Canada', 'date': '2024-03-15', 'sentiment': 'neutral', 'discussion_text': 'Health Canada has updated the guidance on nitrosamine impurities, affecting several schizophrenia treatments.'}","{'type': 'neutral', 'intensity': 'moderate'}"
5f5771dd-1c08-4e89-ab2c-03c9bdc918de,,linkedin,2024-07-22T01:30:01.567Z,https://www.linkedin.com/pulse/paliperidone-extended-release-tablets-market-size-forecast-jszlc,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
0c634c5d-03d8-4f1c-98af-fc62a142873c,"Peripheral Oedema
Lucy Budrus, Clinical Pharmacist

Peripheral oedema is non-specific symptom common among older persons characterised by swelling of lower legs or hands. It results from accumulation of fluid and should be assessed for pitting, tenderness and skin changes.
Timing of oedema is important to assess, along with changes with position, and whether it is unilateral or bilateral:
Unilateral oedema: deep vein thrombosis (DVT), cellulitis or lymphatic obstruction.
Bilateral oedema: systemic diseases such as heart failure, liver failure, kidney failure or severe malabsorption syndromes.

Causes
The most common in older people is venous insufficiency, is related to aging and could be generalised or localised.
Generalised peripheral oedema conditions:
Heart failure
Constrictive pericarditis
Restrictive cardiomyopathy
Hepatic cirrhosis
Nephrotic syndrome
End-stage renal failure
Acute renal failure
Nutritional deficiencies
Medications
Localised peripheral oedema may be caused by lymphoedema, due to inadequate lymphatic drainage, it is typically non-pitting, or lipoedema, DVT, dermatitis or cellulitis.

Medication
CCBs: nifedipine, amlodipine, felodipine, lercanidipine
Vasodilators: minoxidil
NSAIDs
Corticosteroids: prednisone, prednisolone
Antidepressants: escitalopram, mirtazapine, paroxetine, venlafaxine
Estrogens and progestogens
Thiazolidinediones: pioglitazone (Actos)
Antiepileptics: carbamazepine, clobazam, valproate
Antipsychotics: clozapine, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone
Gabapentinoids: gabapentin, pregabalin
Aromatase inhibitors: anastrozole (Arimidex), letrozole (Femara)
Analgesics: fentanyl, hydromorphone, morphine, oxycodone, tramadol
Management
Management should be guided by the underlying condition.
Loop diuretics can be used with heart failure and liver or kidney disease.
Diuretics should not be used to treat peripheral oedema caused by medications.
CCBs may be administered at bedtime to reduce oedema. Dosage reduction or switching to another antihypertensive should be considered. If clinically indicated, the addition of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) to a CCB reduces oedema by about 2/3.
Management of gabapentinoid-induced peripheral oedema should include a review of the appropriateness and ongoing need for these medicines. If deprescribing is not appropriate, a lower dose could be trialled.
For patients with heart failure who do not require hospitalisation, loop diuretics such as furosemide are used.
Treatment for heart failure with reduced ejection fraction (HFrEF) should be optimised with ACE inhibitors, ARB or an ARNI (sacubitrilâ€“valsartan) plus a beta-blocker, mineralocorticoid receptor antagonist (MRA) and an SGLT2 inhibitor (dapagliflozin, empagliflozin).
In patients with preserved ejection fraction (HFpEF) an SGLT2 inhibitor (empagliflozin) should be considered to decrease cardiovascular mortality/ hospitalisation for heart failure.",linkedin,2023-10-18T01:30:01.316Z,https://www.linkedin.com/feed/update/urn:li:activity:7120219438070595584?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7120219438070595584%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Lucy Budrus', 'specialty': 'Clinical Pharmacist', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
68c1f689-57e8-4055-8eee-e608a7c07485,,linkedin,2024-09-12T07:30:12.484Z,https://www.linkedin.com/pulse/global-paliperidone-extended-release-tablets-market-kz2hc,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
46ea8e40-3811-4ae4-b695-4a1675b0b9e3,,linkedin,2024-06-01T03:30:07.550Z,https://www.linkedin.com/pulse/aripiprazole-lauroxil-market-size-analysis-research-yeubc,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
42ea2aa6-1657-47ab-a3ab-27cac113aded,"New Study Published!  ğŸš€ I share our latest research on the comparative effectiveness using NHS Brazil SUS - Bigdata.

Comparative effectiveness of clozapine and non-clozapine atypical antipsychotics provided by the Brazilian National Health System in adults with schizophrenia.

 https://lnkd.in/dFE5qDw5

 ğŸ“Š Main Results: the study followed 375,352 adults with schizophrenia over 15 years.  The overall survival rate was 76.0%.  Clozapine users had a 21% lower risk of death compared to those who used other atypical antipsychotics.  ğŸ’¡ This is the first Brazilian cohort study to evaluate the survival of people with schizophrenia, highlighting the impact of atypical antipsychotics.  Our analysis of real-world data suggests that clozapine has a protective effect on survival compared with olanzapine, risperidone, quetiapine, and ziprasidone.  ğŸ” Comparative effectiveness of clozapine and non-clozapine atypical antipsychotics provided by the Brazilian National Health System in adults with schizophrenia ğŸ‘¥ Authors: Julio Cesar Menezes Vieira Edna Afonso Reis, Augusto Guerra Helian Nunes de Oliveira and Cristina Ruas",linkedin,2024-06-20T15:48:59.608Z,https://www.linkedin.com/feed/update/urn:li:activity:7209583020272496640?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7209583020272496640%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Julio Cesar Menezes Vieira', 'specialty': 'Psychiatry', 'affiliation': 'NHS Brazil SUS', 'geographical_region': 'Brazil'}","[{'name': 'Clozapine', 'type': 'Atypical Antipsychotic', 'indication': 'Schizophrenia', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}, {'name': 'Olanzapine', 'type': 'Atypical Antipsychotic', 'indication': 'Schizophrenia', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}, {'name': 'Risperidone', 'type': 'Atypical Antipsychotic', 'indication': 'Schizophrenia', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}, {'name': 'Quetiapine', 'type': 'Atypical Antipsychotic', 'indication': 'Schizophrenia', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}, {'name': 'Ziprasidone', 'type': 'Atypical Antipsychotic', 'indication': 'Schizophrenia', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}]","{'name': 'Not applicable', 'type': 'Not applicable', 'indication': 'Not applicable', 'manufacturer': 'Not applicable', 'approval_status': 'Not applicable'}","{'type': 'comparison', 'source': 'NHS Brazil SUS - Bigdata', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'Clozapine users had a 21% lower risk of death compared to those who used other atypical antipsychotics.'}","[{'aspect_name': 'Survival Rate', 'description': 'Overall survival rate of adults with schizophrenia', 'comparison': 'The overall survival rate was 76.0% for the cohort studied.'}, {'aspect_name': 'Risk of Death', 'description': 'Comparison of risk of death between clozapine and other atypical antipsychotics', 'comparison': 'Clozapine users had a 21% lower risk of death compared to non-clozapine atypical antipsychotic users.'}]","{'platform': 'LinkedIn', 'date': '2023-10-01', 'sentiment': 'positive', 'discussion_text': 'This is the first Brazilian cohort study to evaluate the survival of people with schizophrenia, highlighting the impact of atypical antipsychotics.'}","{'type': 'positive', 'intensity': 'moderate'}"
8b6e4165-d61a-46fc-9b99-bd44a62f1e6c,Exciting moment to Luye Pharma Group with the approval of the Paliperidone Palmitate extended release injection for treating schizophrenia and schizoaffective disorder by US FDA. Second product with FDA approval after Rykindo (risperidone long acting injection).,linkedin,2024-07-29T05:21:08.374Z,https://www.linkedin.com/feed/update/urn:li:activity:7223558142423359489?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7223558142423359489%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Paliperidone Palmitate', 'type': 'injection', 'indication': 'schizophrenia and schizoaffective disorder', 'manufacturer': 'Luye Pharma Group', 'approval_status': 'FDA approved'}]","{'name': 'Rykindo', 'type': 'injection', 'indication': 'schizophrenia', 'manufacturer': '', 'approval_status': 'FDA approved'}","{'type': 'approval', 'source': 'US FDA', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'Approval of Paliperidone Palmitate extended release injection for treating schizophrenia and schizoaffective disorder.'}","[{'aspect_name': 'Approval Status', 'description': 'The regulatory approval status of the therapies.', 'comparison': 'Both Paliperidone Palmitate and Rykindo have received FDA approval.'}]","{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': 'positive', 'intensity': 'high'}"
873b6fcc-326e-4626-9f3a-104c6c712013,"5 Lifesciences Posts That Creatively Communicate With #Infographics

Professionals in Life Science have become used to visualize complex biological subjects, to make them more accessible to the public and to peers.

Reasons to Use Infographics in Science Communications:

â½ Visuals attract attention and increase engagement
â½ Visuals aid in the processing, storing, and retrieval of information
â½ They offer a powerful alternative to traditional communication methods
â½ Infographics are highly memorable, with people remembering 80% of what they see and do
â½ Infographics can be used in various ways across different media and channels, making them versatile tools
â½ Infographics transcend language barriers and cultural differences, making them an effective way to share messages and information across global organizations

Here are people that routinely use infographics for their LinkedIn posts, spotted this week:

Jeff Bissen ğŸ§¬ğŸŒğŸ””  presents a clear infographic/diagram providing an overview to explain how human-induced pluripotent stem cells (iPSCs) can differentiate into all three germ layers: Ectoderm, Mesoderm, and Endoderm.
https://lnkd.in/dhNGtDXV
#drugdiscovery #drugdevelopment #biotechdiaries

Benjamin McLeod  explains the contents of the AAV genome and describes its four major components using a schematic infographic. https://lnkd.in/dcA87caC
#cgt_simplified #biotechnology #genetherapy #aav #viralvector #science

Maryam Daneshpour  delves into the field of autism medicine development, identifying the key industry players based on the different phases of research. https://lnkd.in/d7vJFk9v
#autism #risperidone #aripiprazole #fda #pharma #autism #pharmaindustry

Nicola Ferrari provides a structured and clear diagram to explain about the activation of fibroblasts and myofibroblasts in normal tissue repair and fibrosis. He also includes a link to the review.
https://lnkd.in/dFGTcxVY
#fibrosis #fibroblast #science #biology

John Gordon explains that Despite progress in cancer immunotherapy, ovarian cancer (OC) prognosis continues to be disappointing. He Introduces a review (which uses a very original infopraphic layout) which primarily aims to dissect the inherent characteristics and behaviours of diverse cells within the immune microenvironment, along with an exploration into its reprogramming and metabolic changes. https://lnkd.in/dXRBeDKE
#ovariancancer #immunotherapy #oc #tumormicroenvironment #immunology

Are you still convinced about the power of infographics to explain complex scientific concepts?

Hi ğŸ‘‹ğŸ», Iâ€™m Lara and I I help small to mid sized Life science companies communicate better by building on brand, personalised visual content bank that aligns with their goals.",linkedin,2024-04-19T12:32:01.858Z,https://www.linkedin.com/feed/update/urn:li:activity:7187065405369171971?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7187065405369171971%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Jeff Bissen', 'specialty': 'Life Sciences', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'infographic', 'source': 'LinkedIn', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'Infographics are highly memorable, with people remembering 80% of what they see and do.'}",[],"{'platform': 'LinkedIn', 'date': '2023-10-01', 'sentiment': 'positive', 'discussion_text': 'Professionals in Life Science have become used to visualize complex biological subjects, to make them more accessible to the public and to peers.'}","{'type': 'positive', 'intensity': 'moderate'}"
5167700b-a794-4885-aec5-f17e0704a165,"Today, we reported our 2024 Second Quarter Financial Results, which underscore continued progress on commercial execution, driving our Growth Portfolio and advancing our pipeline. 

â€œOur second quarter results reflect progress against our strategy to position BMS for long-term, sustainable growth,â€ said Chris Boerner, Ph.D., board chair and CEO, Bristol Myers Squibb. â€œAs we move into the second half of the year, we remain focused on prioritizing opportunities with the greatest growth potential and impact for patients, including the anticipated U.S. launch of KarXT. Weâ€™re also driving operational excellence throughout the company, becoming more agile and strengthening execution.â€

Read more, including important cautionary statements about forward-looking information, here: https://bit.ly/4cXmyuH",linkedin,2024-07-26T14:00:13.132Z,https://www.linkedin.com/feed/update/urn:li:activity:7222601609409667072?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7222601609409667072%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Chris Boerner, Ph.D.', 'specialty': 'CEO', 'affiliation': 'Bristol Myers Squibb', 'geographical_region': 'USA'}","[{'name': 'KarXT', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Bristol Myers Squibb', 'approval_status': 'anticipated U.S. launch'}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'financial report', 'source': 'Bristol Myers Squibb', 'timestamp': '2024-07-01T00:00:00Z', 'insight_text': 'The second quarter results reflect progress against our strategy to position BMS for long-term, sustainable growth, including the anticipated U.S. launch of KarXT.'}",[],"{'platform': 'Bristol Myers Squibb', 'date': '2024-07-01', 'sentiment': 'positive', 'discussion_text': ""The report highlights the company's focus on growth potential and impact for patients.""}","{'type': 'positive', 'intensity': 'moderate'}"
f93deeaa-7461-4267-a7f5-f762a9551d7e,"New antipsychotic that doesnâ€™t block dopamine receptors could be approved this September
KarXT (xanomeline-trospium) is a new antipsychotic drug in Phase 3 testing that acts on the muscarinic receptors instead of directly blocking dopamine receptors. For those concerned with developing TD, this is good news because the central theory of TD development entails blocking of the D2 dopamine receptors. KarXT still decreases dopamine availability in the brain by activating muscarinic receptors instead. If KarXT is approved by the FDA it would be the first antipsychotic since their first use in the 1950s (in the U.S.) that wouldnâ€™t act by blocking dopamine receptors which can cause involuntary movements. KarXT is being developed by Karuna Therapeutics and is scheduled for an FDA decision on September 26, 2024.",linkedin,2024-07-11T14:46:46.383Z,https://www.linkedin.com/feed/update/urn:li:activity:7217177507169497089?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7217177507169497089%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': 'Psychiatry', 'affiliation': 'Karuna Therapeutics', 'geographical_region': 'U.S.'}","[{'name': 'KarXT (xanomeline-trospium)', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Karuna Therapeutics', 'approval_status': 'Pending FDA approval (scheduled for September 26, 2024)'}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'mechanism of action', 'source': 'clinical trial', 'timestamp': '2024-09-26T00:00:00', 'insight_text': 'KarXT acts on muscarinic receptors instead of directly blocking dopamine receptors.'}","[{'aspect_name': 'Mechanism of Action', 'description': 'KarXT does not block dopamine receptors, which is a common mechanism in traditional antipsychotics.', 'comparison': 'KarXT activates muscarinic receptors, decreasing dopamine availability without blocking D2 dopamine receptors.'}]","{'platform': 'clinical trial forum', 'date': '2024-09-26', 'sentiment': 'positive', 'discussion_text': ""KarXT's unique mechanism of action is promising for patients concerned about tardive dyskinesia.""}","{'type': 'positive', 'intensity': 'moderate'}"
d87a9678-a7e7-4e9a-aba8-800be10e25c8,"In a Pharma-funded study, paliperidone palmitate administered once every 6 months to adults with schizophrenia, who were clinically and functionally stable, was associated with favorable long-term outcomes  for up to 3 years.",linkedin,2024-07-19T05:59:01.793Z,https://www.linkedin.com/feed/update/urn:li:activity:7219943799177842689?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7219943799177842689%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'paliperidone palmitate', 'type': 'drug', 'indication': 'schizophrenia', 'manufacturer': 'Pharma', 'approval_status': 'approved'}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'clinical trial', 'source': 'Pharma-funded study', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'Paliperidone palmitate administered once every 6 months to adults with schizophrenia, who were clinically and functionally stable, was associated with favorable long-term outcomes for up to 3 years.'}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
cb17b839-7319-4016-8188-ddfa6eb9e7d8,"I am pleased to Introduce myself as EXECUTIVE DIRECTOR at SRK BIO PHARMA.Â is India's leading manufacturing, marketing, trading, and sourcing company,Â based in Hyderabad, catering to 1000+ clients worldwide in 10+ countries.Â 
Â 
We have a product portfolio spread across categories, namely API, pharmaceuticals, cosmeceuticals, nutraceuticals, 
Â 
Please find below some of our innovative offerings
Â 
Â 
Â 
Â 
Â 
Â 
Â 
API READY STOCK
Â TACROLIMUS, MUPIROCIN, QUINAPYRAMINE SULPHAT EDIETHYL METHYL PHOSPHITE; CLASCOTERONE; LUMACAFTOR; DIFLUPREDNATE; SILODOCIN; CANAGLIFLOZIN, DAPAGLIFLOZIN, IFOSFAMIDE, SUGAMADEX, PACLITAXEL, TENOFOVIR ALFENAMIDE, TRABECTEDIN, SODIUM DEOXY CHOLATE, CLIOQUINOL, PARA BROMO TOLUENE, CYCLO HEXYL BENZENE, BRIVARACETAM, TRICALBENDAZOLE, SAXAGLIPTIN, DEHYDRO CHOLIC ACID, DEOXY CHOLIC ACID, URSO DEOXY CHOLIC ACID, AZIL SARTAN; FLUCONOZOLE; DISODIUM HYDORGEN PHOSPHATE; CALCIUM GLUCOHEPTANOATE
Â Â Â Â Â Â Â CHLORO PHENIRAMINE BASE, RIVAROXABAN, EMPAGLIFLOZIN, EARLOTINIB, AFATINIB, NELABRINE, NILOTINIB, BICALUTAMIDE, BOSATANIB, AZACITADINE, ARIPIPRAZOLE, DESFESTRODINESUCCINATE, NIMSULIDE, CLASCOTERONE, SULFASALAZINE; RUXOLITINIB, BOSUTINIB, DASATINIB, GALANTAMINE HYDROBROMIDE,
Â Â Â Â Â Â Â Â Â REMEDISIVIR, MOLNUPIRAVIR, NIRMATRELVIR, LATANOPROST, TRAVOPROST, TAPENTADOL BIMATOPROST AND CLOPROSRENOL SODIUM, CURCUMIN ANALOGS and ALL ONCO APIâ€™S
Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â COLCHICINE RECEMIC, ABIRATERONE, EZETIMIBE, FEBUXOSTAT, POSACONAZOLE, RUSUVASTATIN, OSIMERTINIB, DOXORUBICIN, EPIRUBICIN, VALRUBICIN, SITAGLIPTIN PHOSPHATE, CALCIUM GLUCONATE MONO HYDRTE
Â 
SUGAMADEXSODIUM; AZTREONAM; AVIBACTAM SODIUM; HYDROXY COBALAMIN; ISAVUCONAZONIUM SULFATE; TRABECTEDIN; ELTRAMBOPAG OLAMINE; EDOXABAN TOSYLATE; RUXOLITINIB PHOSPHATE; OLAPARIB
Â Â Â Â Â Â Â Â Â Â Â 
SRK BIO PHARMA (GST36ADWPT253J2ZX, REGISTERED IN (CDSCO, INDIA)
we are fromÂ SRKBIOPHARMA, REGISTERED IN CDSCO INDIA
Â Â Â Â Â Â Â We believe â€œSupply quality products in the best pricesâ€
We Deal API standards, pharma Raw materials (API, BULK DRUG), specialty chemicals, Impurities, chemical intermediates, GC standards as per the customerâ€™s requirement
Our Customers belongs from API manufacture industries, formulation, SPECIALITY CHEMICALS, Custom synthesis, intermediates manufacturing, veterinary products & pesticides & EXPORTING PHARMACEUTICAL FORMULATIONS, DMF COMPILATIONS
For more information kindly visit our website:Â WWW.SRKBIOPHRMA.CO.IN
MAIL:Â INFO@SRKBIOPHARMA.CO.IN 
We would like to haveÂ businessÂ relationship with you and work for your organization. One of our company representatives would like to personally meet you and discuss how we could help to you
If you are interested, please donâ€™t hesitate to contact us and discuss furtherÂ 
KRISHNAMOHAN_THULLIMILLI@OUTLOOK.COM
9642789508 WhatsApp
WEBSITE: WWW.SRKBIOPHARMA.CO.IN",linkedin,2024-02-28T12:38:05.655Z,https://www.linkedin.com/feed/update/urn:li:activity:7168585150098788353?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7168585150098788353%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Krishnamohan Thullimilli', 'specialty': 'Executive Director', 'affiliation': 'SRK Bio Pharma', 'geographical_region': 'Hyderabad, India'}","[{'name': 'TACROLIMUS', 'type': 'API', 'indication': 'Immunosuppressant', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'MUPIROCIN', 'type': 'API', 'indication': 'Antibiotic', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'QUINAPYRAMINE SULPHATE', 'type': 'API', 'indication': 'Antihypertensive', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'DIFLUPREDNATE', 'type': 'API', 'indication': 'Anti-inflammatory', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'SILODOCIN', 'type': 'API', 'indication': 'Antiviral', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'CANAGLIFLOZIN', 'type': 'API', 'indication': 'Diabetes', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'DAPAGLIFLOZIN', 'type': 'API', 'indication': 'Diabetes', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'IFOSFAMIDE', 'type': 'API', 'indication': 'Chemotherapy', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'SUGAMADEX', 'type': 'API', 'indication': 'Anesthesia', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'PACLITAXEL', 'type': 'API', 'indication': 'Chemotherapy', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'TENOFOVIR ALFENAMIDE', 'type': 'API', 'indication': 'Antiviral', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'TRABECTEDIN', 'type': 'API', 'indication': 'Chemotherapy', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'RIVAROXABAN', 'type': 'API', 'indication': 'Anticoagulant', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'EMPAGLIFLOZIN', 'type': 'API', 'indication': 'Diabetes', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'EARLOTINIB', 'type': 'API', 'indication': 'Chemotherapy', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'AFATINIB', 'type': 'API', 'indication': 'Chemotherapy', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'NILOTINIB', 'type': 'API', 'indication': 'Chemotherapy', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'BICALUTAMIDE', 'type': 'API', 'indication': 'Hormonal therapy', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'AZACITADINE', 'type': 'API', 'indication': 'Chemotherapy', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'ARIPIPRAZOLE', 'type': 'API', 'indication': 'Antipsychotic', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'RUXOLITINIB', 'type': 'API', 'indication': 'Antineoplastic', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'DASATINIB', 'type': 'API', 'indication': 'Chemotherapy', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'GALANTAMINE HYDROBROMIDE', 'type': 'API', 'indication': ""Alzheimer's"", 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'REMEDISIVIR', 'type': 'API', 'indication': 'Antiviral', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'MOLNUPIRAVIR', 'type': 'API', 'indication': 'Antiviral', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'NIRMATRELVIR', 'type': 'API', 'indication': 'Antiviral', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'LATANOPROST', 'type': 'API', 'indication': 'Glaucoma', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'TRAVOPROST', 'type': 'API', 'indication': 'Glaucoma', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'TAPENTADOL', 'type': 'API', 'indication': 'Pain management', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'BIMATOPROST', 'type': 'API', 'indication': 'Glaucoma', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'CLOPROSRENOL SODIUM', 'type': 'API', 'indication': 'Ophthalmic', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'CURCUMIN ANALOGS', 'type': 'API', 'indication': 'Anti-inflammatory', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'COLCHICINE RECEMIC', 'type': 'API', 'indication': 'Gout', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'ABIRATERONE', 'type': 'API', 'indication': 'Hormonal therapy', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'EZETIMIBE', 'type': 'API', 'indication': 'Cholesterol', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'FEBUXOSTAT', 'type': 'API', 'indication': 'Gout', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'POSACONAZOLE', 'type': 'API', 'indication': 'Antifungal', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'RUSUVASTATIN', 'type': 'API', 'indication': 'Cholesterol', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'OSIMERTINIB', 'type': 'API', 'indication': 'Chemotherapy', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'DOXORUBICIN', 'type': 'API', 'indication': 'Chemotherapy', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'EPIRUBICIN', 'type': 'API', 'indication': 'Chemotherapy', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'VALRUBICIN', 'type': 'API', 'indication': 'Chemotherapy', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'SITAGLIPTIN PHOSPHATE', 'type': 'API', 'indication': 'Diabetes', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}, {'name': 'CALCIUM GLUCONATE MONO HYDRTE', 'type': 'API', 'indication': 'Supplement', 'manufacturer': 'SRK Bio Pharma', 'approval_status': 'Registered'}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'comparison', 'source': 'company website', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'SRK Bio Pharma offers a wide range of APIs including those used in schizophrenia treatments, but specific details on efficacy and safety are not provided.'}","[{'aspect_name': 'Efficacy', 'description': 'The effectiveness of the therapies in treating schizophrenia.', 'comparison': 'No specific data provided on efficacy for schizophrenia treatments.'}, {'aspect_name': 'Safety', 'description': 'The safety profile of the therapies used for schizophrenia.', 'comparison': 'No specific data provided on safety for schizophrenia treatments.'}, {'aspect_name': 'Market Impact', 'description': 'The potential market impact of the therapies for schizophrenia.', 'comparison': 'No specific data provided on market impact for schizophrenia treatments.'}]","{'platform': 'company website', 'date': '2023-10-01', 'sentiment': 'neutral', 'discussion_text': 'The company is open to discussions regarding partnerships and collaborations in the field of schizophrenia treatments.'}","{'type': 'neutral', 'intensity': 'low'}"
b0c7d293-c4c6-4f5c-95be-211ccf80bea8,"Treatment of ultra treatment-resistant psychosis in a carceral setting is a significant portion of my current practice. Recently achieved remarkable success using a cascading regimen of Paliperidone Palmitate and Abilify Maintena (Otsuka) where Clozapine was not an option. This case needs further research but may serve as a potential option for psychiatrists serving this very challenging population. A special thank you to colleagues at Centurion Health, Geisinger Commonwealth School of Medicine and Pennsylvania Department of Corrections .",linkedin,2024-08-27T22:32:27.082Z,https://www.linkedin.com/feed/update/urn:li:activity:7234326928638328833?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7234326928638328833%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Not specified', 'specialty': 'Psychiatry', 'affiliation': 'Centurion Health, Geisinger Commonwealth School of Medicine, Pennsylvania Department of Corrections', 'geographical_region': 'Not specified'}","[{'name': 'Paliperidone Palmitate', 'type': 'drug', 'indication': 'Ultra treatment-resistant psychosis', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}, {'name': 'Abilify Maintena', 'type': 'drug', 'indication': 'Ultra treatment-resistant psychosis', 'manufacturer': 'Otsuka', 'approval_status': 'Not specified'}]","{'name': 'Not specified', 'type': 'Not specified', 'indication': 'Not specified', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}","{'type': 'research suggestion', 'source': 'clinical practice', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'This case needs further research but may serve as a potential option for psychiatrists serving this very challenging population.'}","[{'aspect_name': 'Efficacy', 'description': 'Effectiveness of the treatment regimen in ultra treatment-resistant psychosis', 'comparison': 'Remarkable success using a cascading regimen of Paliperidone Palmitate and Abilify Maintena where Clozapine was not an option.'}]","{'platform': 'Not specified', 'date': '2023-10-01', 'sentiment': 'positive', 'discussion_text': 'A special thank you to colleagues at Centurion Health, Geisinger Commonwealth School of Medicine and Pennsylvania Department of Corrections.'}","{'type': 'positive', 'intensity': 'moderate'}"
a1a90376-b992-4a25-b12c-6e99c7778cff,"Pearls for treating late-life #depression in new review. Go to full dose (but start low/slow), use psychotherapy, avoid benzo/anticholinergics/antihistaminergics, and consider aripiprazole augmentation, ketamine, or ECT if no response:
https://lnkd.in/gbxJUZXx

---------------------------------------------------
Follow for research updates from the editor of the Carlat #Psychiatry Report #mentalhealth",linkedin,2023-12-06T13:45:09.634Z,https://www.linkedin.com/feed/update/urn:li:activity:7138161447179616256?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7138161447179616256%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Editor of the Carlat Psychiatry Report', 'specialty': 'Psychiatry', 'affiliation': 'Carlat Psychiatry Report', 'geographical_region': 'Not specified'}","[{'name': 'Aripiprazole', 'type': 'drug', 'indication': 'augmentation for late-life depression', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}, {'name': 'Ketamine', 'type': 'drug', 'indication': 'augmentation for late-life depression', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}, {'name': 'ECT (Electroconvulsive Therapy)', 'type': 'procedure', 'indication': 'augmentation for late-life depression', 'manufacturer': 'Not applicable', 'approval_status': 'Not specified'}]","{'name': 'Psychotherapy', 'type': 'therapy', 'indication': 'treatment for late-life depression', 'manufacturer': 'Not applicable', 'approval_status': 'Not applicable'}","{'type': 'treatment recommendations', 'source': 'Carlat Psychiatry Report', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'Go to full dose (but start low/slow), use psychotherapy, avoid benzo/anticholinergics/antihistaminergics, and consider aripiprazole augmentation, ketamine, or ECT if no response.'}","[{'aspect_name': 'Dosage Strategy', 'description': 'Starting low and going to full dose for treatment.', 'comparison': 'Start low/slow and then increase to full dose.'}, {'aspect_name': 'Therapy Types', 'description': 'Different types of therapies recommended for treatment.', 'comparison': 'Use psychotherapy and consider drug augmentation.'}, {'aspect_name': 'Avoidance of Certain Medications', 'description': 'Medications to avoid in treatment.', 'comparison': 'Avoid benzodiazepines, anticholinergics, and antihistaminergics.'}]","{'platform': 'LinkedIn', 'date': '2023-10-01', 'sentiment': 'neutral', 'discussion_text': 'Pearls for treating late-life depression in new review.'}","{'type': 'neutral', 'intensity': 'low'}"
30b794aa-552b-47d7-9395-00e65acfdc27,"ğŸ”¬ New Article in #JDDST Released! ğŸ“š One of our latest scientific publications offers valuable insights into 'Biorelevant in vitro drug release conditions ameliorate in-vitro-in-vivo relationship of parenteral risperidone microspheres'.  Congratulations to the diligent researchers involved! 

The full article is available until November 16, 2023 via this link:  https://lnkd.in/ezmWNf8b


ğŸ™Œ #SciencePublication #ResearchUpdate #NewDiscoveries",linkedin,2023-10-09T16:30:58.292Z,https://www.linkedin.com/feed/update/urn:li:activity:7117184678670790656?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7117184678670790656%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
d395cb4c-21ac-48c0-8122-8f96457bca08,,linkedin,2024-01-18T04:21:51.097Z,https://www.linkedin.com/pulse/aripiprazole-drug-market-growth-research-jwjqf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
81bdbeab-94f9-460f-9ed5-f7acbf1cb046,Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months https://t.co/YvK05hVXuc #EurekaMag,linkedin,2023-06-14T04:35:09.252Z,https://www.linkedin.com/feed/update/urn:li:activity:7074605157065388032?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7074605157065388032%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': 'Psychiatry', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Long-acting risperidone', 'type': 'drug', 'indication': 'schizophrenia', 'manufacturer': '', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'clinical trial results', 'source': 'EurekaMag', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months.'}",[],"{'platform': 'Twitter', 'date': '2023-10-01', 'sentiment': 'positive', 'discussion_text': 'Discussion on the efficacy of long-acting risperidone in achieving long-term remission in schizophrenia.'}","{'type': 'positive', 'intensity': 'moderate'}"
7d3e0c5f-fe00-40cc-9013-10b5e1fd8b25,"The FDA has approved Erzofri, a paliperidone palmitate extended-release injectable suspension for the treatment of adults with schizophrenia and schizoaffective disorder. https://lnkd.in/gTptKfrN",linkedin,2024-07-30T13:42:02.832Z,https://www.linkedin.com/feed/update/urn:li:activity:7224046587822362624?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7224046587822362624%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Erzofri', 'type': 'injectable suspension', 'indication': 'schizophrenia and schizoaffective disorder', 'manufacturer': '', 'approval_status': 'FDA approved'}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
b67f008b-c56b-44e3-bdf5-9bfdcf0dbde4,,linkedin,2024-06-23T18:20:03.609Z,https://www.linkedin.com/pulse/paliperidone-api-market-trends-key-insights-2024-2031-econopulse-02xqf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
50bb3d9f-7027-46db-b4c2-9686f0a45f17,"Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program. Presentations include data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, from a once-monthly intramuscular injection of Invega Sustenna. The results were presented at the Psych Congress Elevate 2024 Annual Meeting taking place from May 30 â€“ June 2 in Las Vegas, Nevada.

â€œUZEDY is a long-acting formulation of risperidone with an innovative delivery system that requires no loading dose or oral supplementation and can be dosed at one- or two-month intervals to help with prevention of relapse. It is administered subcutaneously under the skin instead of intramuscularly, which is an important feature to discuss with patients,â€ said Eric A. Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer at Teva. â€œWe are proud to share these clinical insights that may help healthcare providers understand more about switching between long-acting options for their schizophrenia patients.â€

In a population pharmacokinetic (PopPK) analysis, simulations were performed to predict PK exposures when switching to UZEDY 4-6 weeks at steady state after the last injection of once-monthly paliperidone palmitate. Model simulations showed that switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate yielded generally higher PK parameters, both within the total active moiety range for oral risperidone. Comparable doses included UZEDY at 125 mg (once-monthly dosing) or 250 mg (once-every-two-months dosing) to 234 mg of once-monthly paliperidone palmitate. The analysis aims to address the knowledge gap as limited clinical data currently exist to inform strategies for switching between the various available LAI treatment options with differing PK properties.
Any switching strategy should be determined by clinicians on an individual basis, considering factors such as patient preference, scheduling convenience and potential tolerability issues or risk of symptom breakthrough.

â€œThe treatment and management of schizophrenia is a journey and many patients may see their needs evolve over time due to challenges with symptom control or simply due to a change in dosing preference,â€ said Christoph Correll, MD, Professor of Psychiatry at the Zucker School of Medicine, Hempstead, NY. â€œResearchers and clinicians like myself rely on analyses like these to understand strategies for switching between long-acting injectable options and help ensure each of our patients is on the most appropriate treatment.â€
#schizophrenia #research #PsychCongressElevate2024
#risperidone #UZEDY #TevaPharm #Teva #PivottoGrowth 
ğŸ‘‰ News & Media (tevausa.com)",linkedin,2024-06-02T15:39:35.891Z,https://www.linkedin.com/feed/update/urn:li:activity:7203057674291232769?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7203057674291232769%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Eric A. Hughes, MD, PhD', 'specialty': 'Global R&D and Chief Medical Officer', 'affiliation': 'Teva Pharmaceuticals', 'geographical_region': 'U.S.'}","[{'name': 'UZEDY', 'type': 'long-acting injectable', 'indication': 'schizophrenia', 'manufacturer': 'Teva Pharmaceuticals', 'approval_status': 'not specified'}]","{'name': 'Invega Sustenna', 'type': 'long-acting injectable', 'indication': 'schizophrenia', 'manufacturer': 'not specified', 'approval_status': 'not specified'}","{'type': 'clinical strategy', 'source': 'Psych Congress Elevate 2024 Annual Meeting', 'timestamp': '2024-05-30T00:00:00', 'insight_text': 'UZEDY is a long-acting formulation of risperidone with an innovative delivery system that requires no loading dose or oral supplementation and can be dosed at one- or two-month intervals to help with prevention of relapse.'}","[{'aspect_name': 'pharmacokinetics', 'description': 'Comparison of PK parameters when switching to UZEDY from paliperidone palmitate.', 'comparison': 'Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate yielded generally higher PK parameters.'}, {'aspect_name': 'dosing frequency', 'description': 'Dosing frequency comparison between UZEDY and Invega Sustenna.', 'comparison': 'UZEDY can be dosed at one- or two-month intervals compared to once-monthly dosing of Invega Sustenna.'}]","{'platform': 'Psych Congress Elevate 2024 Annual Meeting', 'date': '2024-05-30', 'sentiment': 'positive', 'discussion_text': 'The treatment and management of schizophrenia is a journey and many patients may see their needs evolve over time due to challenges with symptom control or simply due to a change in dosing preference.'}","{'type': 'positive', 'intensity': 'moderate'}"
d7dfaace-8522-41c4-b8eb-20687fbdb97d,"I would like to share some insight about using Paliperidone Palmitate versus other  depot antipsychotics. The conventional depot APs in our country are Fluphenazine, Haloperidol, Risperidone and Olanzapine. I hope this understanding will aid our fellow health care professionals in achieving better results in treatment.",linkedin,2023-01-18T14:16:02.074Z,https://www.linkedin.com/pulse/paliperidone-palmitate-vs-other-conventional-depot-stefan-trpkovski,"{'name': 'Not specified', 'specialty': 'Psychiatry', 'affiliation': 'Not specified', 'geographical_region': 'Not specified'}","[{'name': 'Paliperidone Palmitate', 'type': 'Depot Antipsychotic', 'indication': 'Schizophrenia', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}, {'name': 'Fluphenazine', 'type': 'Depot Antipsychotic', 'indication': 'Schizophrenia', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}, {'name': 'Haloperidol', 'type': 'Depot Antipsychotic', 'indication': 'Schizophrenia', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}, {'name': 'Risperidone', 'type': 'Depot Antipsychotic', 'indication': 'Schizophrenia', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}, {'name': 'Olanzapine', 'type': 'Depot Antipsychotic', 'indication': 'Schizophrenia', 'manufacturer': 'Not specified', 'approval_status': 'Not specified'}]","{'name': 'Not applicable', 'type': 'Not applicable', 'indication': 'Not applicable', 'manufacturer': 'Not applicable', 'approval_status': 'Not applicable'}","{'type': 'comparison', 'source': 'Not specified', 'timestamp': 'Not specified', 'insight_text': 'Insight about using Paliperidone Palmitate versus other depot antipsychotics.'}","[{'aspect_name': 'Efficacy', 'description': 'Comparison of the effectiveness of different depot antipsychotics in treating schizophrenia.', 'comparison': 'Paliperidone Palmitate is compared to Fluphenazine, Haloperidol, Risperidone, and Olanzapine.'}, {'aspect_name': 'Safety', 'description': 'Assessment of the safety profiles of the depot antipsychotics.', 'comparison': 'Safety profiles of Paliperidone Palmitate versus other depot antipsychotics are not detailed.'}, {'aspect_name': 'Market Impact', 'description': 'Discussion on the market presence and impact of these therapies.', 'comparison': 'Market impact of Paliperidone Palmitate compared to other depot antipsychotics is not discussed.'}]","{'platform': 'Not specified', 'date': 'Not specified', 'sentiment': 'Not specified', 'discussion_text': 'Discussion on the use of Paliperidone Palmitate versus other depot antipsychotics.'}","{'type': 'Not specified', 'intensity': 'Not specified'}"
ba25d77c-a06d-4fd8-8b2a-e1d5415b4897,"ğ‚ğ¥ğ¢ğœğ¤ ğ¡ğğ«ğ ğ“ğ¨ https://lnkd.in/dKScmk59 ğ ğğ­ ğ°ğğ¥ğ¥-ğ«ğğ¬ğğšğ«ğœğ¡ ğ«ğğ©ğ¨ğ«ğ­ #risperidoneapimarket #risperidone #api #risperidoneapimarketsizeÂ #risperidoneapimarketshare #risperidoneapimarketforecast #purity98%,purity99%,others #schizophreniatreatment,bipolardisordertreatment,#tevapharmaceuticalindustriesltd. #mylann.v. #dr.reddy'slaboratoriesltd. #zhejianghuahaipharmaceuticalco. #ltd. #torrentpharmaceuticalsltd. #jubilantlifesciencesltd. #aurobindopharmalimited #sunpharmaceuticalindustriesltd. #heterodrugslimited #intaspharmaceuticalsltd. #",linkedin,2024-08-09T15:30:03.375Z,https://www.linkedin.com/pulse/europe-risperidone-api-market-developments-application-44wjf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}","[{'name': 'Risperidone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Teva Pharmaceutical Industries Ltd.', 'approval_status': ''}, {'name': 'Risperidone', 'type': 'drug', 'indication': 'Bipolar Disorder', 'manufacturer': ""Dr. Reddy's Laboratories Ltd."", 'approval_status': ''}, {'name': 'Risperidone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Zhejiang Huahai Pharmaceutical Co., Ltd.', 'approval_status': ''}, {'name': 'Risperidone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Torrent Pharmaceuticals Ltd.', 'approval_status': ''}, {'name': 'Risperidone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Jubilant Life Sciences Ltd.', 'approval_status': ''}, {'name': 'Risperidone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Aurobindo Pharma Limited', 'approval_status': ''}, {'name': 'Risperidone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Sun Pharmaceutical Industries Ltd.', 'approval_status': ''}, {'name': 'Risperidone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Hetero Drugs Limited', 'approval_status': ''}, {'name': 'Risperidone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Intas Pharmaceuticals Ltd.', 'approval_status': ''}]","{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': 'market impact', 'source': 'LinkedIn', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'Risperidone is a leading treatment for schizophrenia with various manufacturers contributing to the market.'}","[{'aspect_name': 'Market Share', 'description': 'The distribution of market share among different manufacturers of Risperidone.', 'comparison': ""Teva Pharmaceutical Industries Ltd. holds a significant share, followed by Dr. Reddy's Laboratories Ltd. and others.""}, {'aspect_name': 'Efficacy', 'description': 'The effectiveness of Risperidone in treating schizophrenia.', 'comparison': 'Risperidone has shown positive outcomes in clinical trials for schizophrenia treatment.'}, {'aspect_name': 'Safety', 'description': 'The safety profile of Risperidone in patients.', 'comparison': 'Risperidone is generally well-tolerated, but side effects can occur.'}]","{'platform': 'LinkedIn', 'date': '2023-10-01', 'sentiment': 'positive', 'discussion_text': 'The discussions around Risperidone highlight its efficacy and safety in treating schizophrenia.'}","{'type': 'positive', 'intensity': 'moderate'}"
83fa1b2a-a38d-4255-9ade-13ccd4b96cb8,"A true milestone for any PhD: the first paper has been published! Our systematic review on the influence of CYP2C19 and CYP2D6 on side effects of aripiprazole and risperidone is now available online in the Journal of Psychiatric Research:
https://lnkd.in/ekMgkxfM

Many thanks to my supervisors Roos van Westrhenen and Therese van Amelsvoort, and my co-author Kristian Kleine Schaars for their effort and contributions!",linkedin,2024-04-16T12:25:21.693Z,https://www.linkedin.com/feed/update/urn:li:activity:7185976563358691328?updateEntityUrn=urn%3Ali%3Afs_updateV2%3A%28urn%3Ali%3Aactivity%3A7185976563358691328%2CFEED_DETAIL%2CEMPTY%2CDEFAULT%2Cfalse%29,"{'name': 'Roos van Westrhenen', 'specialty': 'Psychiatry', 'affiliation': 'Unknown', 'geographical_region': 'Unknown'}","[{'name': 'Aripiprazole', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Unknown', 'approval_status': 'Approved'}, {'name': 'Risperidone', 'type': 'drug', 'indication': 'Schizophrenia', 'manufacturer': 'Unknown', 'approval_status': 'Approved'}]","{'name': 'Unknown', 'type': 'Unknown', 'indication': 'Unknown', 'manufacturer': 'Unknown', 'approval_status': 'Unknown'}","{'type': 'systematic review', 'source': 'Journal of Psychiatric Research', 'timestamp': '2023-10-01T00:00:00Z', 'insight_text': 'The systematic review discusses the influence of CYP2C19 and CYP2D6 on side effects of aripiprazole and risperidone.'}","[{'aspect_name': 'Side Effect Profile', 'description': 'Comparison of side effects associated with aripiprazole and risperidone based on CYP2C19 and CYP2D6 metabolism.', 'comparison': 'The review highlights how genetic variations in CYP2C19 and CYP2D6 can influence the side effects experienced by patients taking aripiprazole and risperidone.'}]","{'platform': 'Journal of Psychiatric Research', 'date': '2023-10-01', 'sentiment': 'positive', 'discussion_text': 'The publication of the systematic review is seen as a significant contribution to understanding the pharmacogenomics of schizophrenia treatments.'}","{'type': 'positive', 'intensity': 'high'}"
c0bcfc0a-eb4e-4a9a-8fe2-06289594faab,"ğ‚ğ¥ğ¢ğœğ¤ ğ¡ğğ«ğ ğ“ğ¨ https://lnkd.in/dQ66Rhrb ğ ğğ­ ğ°ğğ¥ğ¥-ğ«ğğ¬ğğšğ«ğœğ¡ ğ«ğğ©ğ¨ğ«ğ­ ........................................................................................................................................................#Innovation, #Management, #DigitalMarketing, #Entrepreneurship, #Startups, #Leadership, #BusinessGrowth, #SustainableDevelopment, #EconomicPolicy, #HumanResources, #Marketing, #Technology, #Careers, #SocialMedia, #Entrepreneurâ€‹ #paliperidonemarket #paliperidone #paliperidonemarketsize #paliperidonemarketshare #paliperidonemarketforecast #podcasting #podcastlife #podcastersoflinkedin #podcastcommunity #podcastlisteners #audiocontent #podcastproduction #podcasthost #podcastinterview #podcasttips #podcastrecommendations #podcastseries #podcastmarketing #podcastcreation #podcastworld #anugrahachemicals #megafine #jubilantpharma #rablon #lakshmi #arunodayapharma #arlifesciences",linkedin,2024-06-24T05:00:11.158Z,https://www.linkedin.com/pulse/paliperidone-market-size-trends-forecast-vtuxf,"{'name': '', 'specialty': '', 'affiliation': '', 'geographical_region': ''}",[],"{'name': '', 'type': '', 'indication': '', 'manufacturer': '', 'approval_status': ''}","{'type': '', 'source': '', 'timestamp': '', 'insight_text': ''}",[],"{'platform': '', 'date': '', 'sentiment': '', 'discussion_text': ''}","{'type': '', 'intensity': ''}"
